190 results on '"Joop Jukema"'
Search Results
2. Publisher Correction: Fuelling conditions at staging sites can mitigate Arctic warming effects in a migratory bird
- Author
-
Eldar Rakhimberdiev, Sjoerd Duijns, Julia Karagicheva, Cornelis J. Camphuysen, VRS Castricum, Anne Dekinga, Rob Dekker, Anatoly Gavrilov, Job ten Horn, Joop Jukema, Anatoly Saveliev, Mikhail Soloviev, T. Lee Tibbitts, Jan A. van Gils, and Theunis Piersma
- Subjects
Science - Abstract
In the original HTML version of this Article, the order of authors within the author list was incorrect. The consortium VRS Castricum was incorrectly listed after Theunis Piersma and should have been listed after Cornelis J. Camphuysen. This error has been corrected in the HTML version of the Article; the PDF version was correct at the time of publication.
- Published
- 2018
- Full Text
- View/download PDF
3. Goede prognose voor terugverwezen hartinfarctpatiënten
- Author
-
Bart Mertens, Huug van Duijn, Nicoline van Hattem, Matthijs Numans, Rachid Abou, Mathijs C. Bodde, J.J. Bax, M.J. Schalij, and Joop Jukema
- Subjects
03 medical and health sciences ,030505 public health ,0305 other medical science ,Family Practice - Abstract
Het is belangrijk om te achterhalen welke ST-elevatiemyocardinfarctpatienten tot de laagrisicogroep behoren, zodat ze naar de huisarts terugverwezen kunnen worden. Wij onderzochten wat de prognose is van patienten met een ST-elevatiemyocardinfarct die na 1 jaar behandeling volgens een specifiek protocol naar de huisarts zijn terugverwezen.
- Published
- 2020
4. The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
- Author
-
Stella Trompet, D M van Velzen, Ian Ford, David J. Stott, Joop Jukema, S. Simsek, Laurien E Zijlstra, Simon P. Mooijaart, and M. van Buren
- Subjects
endocrine system ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Renal function ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Gastroenterology ,Endocrinology ,cardiovascular disease ,Internal medicine ,Internal Medicine ,Clinical endpoint ,Medicine ,kidney function ,Subclinical infection ,lcsh:RC648-665 ,thyroid function ,business.industry ,Research ,Thyroid disease ,Thyroid ,medicine.disease ,older patients ,R1 ,medicine.anatomical_structure ,Thyroid function ,business ,hormones, hormone substitutes, and hormone antagonists ,Pravastatin ,Hormone ,medicine.drug - Abstract
Objective Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardiovascular outcomes. Methods In total, 5804 patients were included in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid function at baseline and 6 months, 294 because of medication use that could influence thyroid function, and 16 because of missing kidney or thyroid values. Participants with normal fT4 were classified, based on TSH both at inclusion and 6 months, into three groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 mIU/L); and subclinical hyperthyroidism (TSH 60 mL/min/1.73 m2. The primary endpoint consists of death from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke. Results Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 (94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No statistically significant relationship was found between subclinical thyroid dysfunction and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism with euthyroidism. Neither was this relationship present in any of the strata of kidney function, nor did kidney function interact with subclinical thyroid dysfunction in the association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism and 0.388 for subclinical hypothyroidism). Conclusions In this secondary analysis from PROSPER, we found no evidence that the potential association between thyroid hormones and cardiovascular disease is modified by kidney function in older patients with subclinical thyroid dysfunction.
- Published
- 2020
5. Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability
- Author
-
Tove Fall, Anubha Mahajan, Dmitry Shungin, B. Balkau, Gerjan Navis, A. Metspalu, Anneli Pouta, Andrew A. Hicks, Ilja M. Nolte, Ian Ford, Aroon D. Hingorani, Stefan R Bornstein, Anuj Goel, Rona J. Strawbridge, Niek Verweij, Sarah H. Wild, Patricia B. Munroe, T.B. Harris, Jaana Lindström, Johnson Pcd., Nita G. Forouhi, Pierre Meneton, Patricia A. Peyser, Sarin A-P., Andrea Ganna, Timothy M. Frayling, Patrik K. E. Magnusson, Joanne M. Meyer, Yongmei Liu, Jeanette M. Stafford, Christian Herder, L Zudina, Maria G. Stathopoulou, May E. Montasser, Nicholas D. Hastie, Inês Barroso, Schwarz Peh., James B. Meigs, Perttu Salo, George Davey Smith, Gonneke Willemsen, Christopher J. Groves, Erik P A Van Iperen, M. A. Province, Veikko Salomaa, Naveed Sattar, Serena Sanna, Maria Dimitriou, Joop Jukema, Ulrika Krus, Albert V. Smith, Markku Laakso, James F. Wilson, George Nicholson, Loic Yengo, Tatijana Zemunik, Per Eriksson, Harold Snieder, Peter P. Pramstaller, Claudia Langenberg, R. Rauramaa, Alan R. Shuldiner, Pau Navarro, Veronique Vitart, Ross M. Fraser, Aaron Isaacs, C. Lecoeur, Jesper R. Gådin, Jackie F. Price, Letizia Marullo, L.F. Bielak, Sirkka Keinänen-Kiukaanniemi, Amélie Bonnefond, Michael Stumvoll, Alessia Faggian, Anke Tönjes, Tomohiro Tanaka, Wieland Kiess, Harry Campbell, Josée Dupuis, David Altshuler, João Fadista, Winfried März, G K Hovingh, Thomas Illig, Toby Johnson, H Grallert, Kari Stefansson, Reedik Mägi, Palmer Cna., de Geus Ejcn., Martina Müller-Nurasyid, Karen Kapur, Philippe Froguel, Dorret I. Boomsma, Anders Franco-Cereceda, Marcus E. Kleber, Boehnke M, Olga D. Carlson, Ozren Polasek, Andrew P. Morris, Alex S. F. Doney, Najaf Amin, Sara M. Willems, Vilmundur Gudnason, Jose C. Florez, Jeffery R. O'Connell, Nancy L. Pedersen, T. Saaristo, Wolffenbuttel Bhr., M. I. J. Uusitupa, Longda Jiang, Iva Miljkovic, James S. Pankow, Caroline Hayward, Hugh Watkins, Vasiliki Lagou, Johanna Kuusisto, Jaakko Tuomilehto, Alan F. Wright, Josephine M. Egan, Perry Jrb., C M van Duijn, Valeriya Lyssenko, Leif Groop, Stefania Bandinelli, Nigel W. Rayner, Tõnu Esko, Stela McLachlan, Momoko Horikoshi, Eric Boerwinkle, Rick Jansen, Richard N. Bergman, Gudmar Thorleifsson, Lyle J. Palmer, Vilmantas Giedraitis, Peter Kovacs, Nicholas J. Wareham, Luigi Ferrucci, N J Timpson, D Rybin, Anne U. Jackson, Tiinamaija Tuomi, Gonçalo R. Abecasis, Harst Pvd., Meena Kumari, Albert Hofman, Chiara Scapoli, Evelin Mihailov, Josine L. Min, Anders Hamsten, Hottenga J-J., Loos Rjf., Lars Lind, Ulf de Faire, Jaakko Kaprio, Guo Li, Beate St Pourcain, C Gieger, Amanda J. Bennett, Anna Ulrich, Nabila Bouatia-Naji, Satu Männistö, Antigone S. Dimas, Jarvelin M-R., Günther Silbernagel, F Karpe, A. Körner, David S. Siscovick, M Blüher, Rebecca J. Webster, Erik Ingelsson, Susan Campbell, Mika Kivimäki, Laura J. Rasmussen-Torvik, Heikki A. Koistinen, Sophie Visvikis-Siest, Bernhard O. Boehm, Inga Prokopenko, Ping An, Emmanouil T. Dermitzakis, Cecilia M. Lindgren, Kardia Slr., Richa Saxena, Igor Rudan, Richard M. Watanabe, Jian'an Luan, Marika Kaakinen, Shin S-Y., George Dedoussis, Panagiotis Deloukas, Mark I. McCarthy, Barbara Thorand, B.W.J.H. Penninx, Peter Vollenweider, Paul W. Franks, Leena Kinnunen, Markus Perola, Yvonne Boettcher, Timo A. Lakka, Nicole Soranzo, Stavroula Kanoni, Bakker Sjl., Winkelmann Br, The Wellcome Trust Centre for Human Genetics [Oxford], University of Oxford [Oxford], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Institute of Genomics [Tartu, Estonia], University of Tartu, Vrije Universiteit Amsterdam [Amsterdam] (VU), Vrije Universiteit Medical Centre (VUMC), Helmholtz-Zentrum München (HZM), University of Cambridge [UK] (CAM), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (GI3M), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Università degli Studi di Ferrara (UniFE), Boston University [Boston] (BU), VU University Medical Center [Amsterdam], University of Bristol [Bristol], Biomedical Sciences Research Centre Alexander Fleming [Vari, Greece] (BSRC), Imperial College London, Karolinska Institutet [Stockholm], Institute for Molecular Bioscience, University of Queensland [Brisbane], Statens Serum Institut [Copenhagen], Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University [Maastricht], MRC Institute of Genetics and Molecular Medicine [Edinburgh] (IGMM), University of Edinburgh-Medical Research Council, National Institute on Aging [Baltimore, MD, USA] (NIH), University of Michigan [Ann Arbor], University of Michigan System, University of Maryland School of Medicine, University of Maryland System, The University of Western Australia (UWA), Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Massachusetts General Hospital [Boston], Harvard Medical School [Boston] (HMS), Wake Forest University, National Institute for Health and Welfare [Helsinki], The Wellcome Trust Sanger Institute [Cambridge], University of Iceland [Reykjavik], University of Washington [Seattle], University of Groningen [Groningen], University of Glasgow, William Harvey Research Institute, Barts and the London Medical School, Université de Lausanne (UNIL), deCODE genetics [Reykjavik], Northwestern University Feinberg School of Medicine, Uppsala Universitet [Uppsala], University of Edinburgh, Medical Faculty [Mannheim], University of Graz, Ludwig-Maximilians-Universität München (LMU), Johannes Gutenberg - Universität Mainz (JGU), Institute for Molecular Medicine Finland [Helsinki] (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki-University of Helsinki, Umeå University, Skane University Hospital [Malmo], Lund University [Lund], RIKEN Center for Integrative Medical Sciences [Yokohama] (RIKEN IMS), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche [Roma] (CNR), University Medical Center Groningen [Groningen] (UMCG), Universität Leipzig [Leipzig], Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Split, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), University of Eastern Finland, Harokopio University of Athens, European Academy Bozen/Bolzano (EURAC), University of Kuopio, German Center for Diabetes Research - Deutsches Zentrum für Diabetesforschung [Neuherberg] (DZD), University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Ninewells Hospital and Medical School [Dundee], University College of London [London] (UCL), University of Essex, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], University of Helsinki, Leiden University Medical Center (LUMC), Institute of Cardiovascular and Medical Sciences [Glasgow], University of Oulu, The University of Texas Health Science Center at Houston (UTHealth), University of Minnesota Medical School, University of Minnesota System, Keck School of Medicine [Los Angeles], University of Southern California (USC), Amsterdam UMC, University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Lee Kong Chian School of Medicine, Nanyang Technological University (NTU), Universität Heidelberg [Heidelberg], King Abdulaziz University, Pirkanmaa Hospital District, Tampere University Hospital, Cedars-Sinai Medical Center, Danube University Krems, Harvard School of Public Health, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institute of Epidemiology [Neuherberg] (EPI), German Research Center for Environmental Health - Helmholtz Center München (GmbH), Hannover Medical School [Hannover] (MHH), Universität zu Lübeck [Lübeck], University of Exeter, Regeneron Pharmaceuticals [Tarrytown], University of Adelaide, Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), National Institute on Aging [Bethesda, USA] (NIA), National Institutes of Health [Bethesda] (NIH), Icahn School of Medicine at Mount Sinai [New York] (MSSM), Harvard T.H. Chan School of Public Health, John Radcliffe Hospital [Oxford University Hospital], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Université de Genève (UNIGE), Big Data Institute, University of Surrey (UNIS), University of Bergen (UiB), Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Stanford Cardiovascular Institute, University of Liverpool, University of Manchester [Manchester], Institute of Biochemistry and Genetics of Ufa Scientific Centre, Russian Academy of Sciences [Moscow] (RAS), Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, SIEST, Sofia, PreciDIAB Institute, the holistic approach of personal diabets care - - PreciDIAB2018 - ANR-18-IBHU-0001 - IBHU - VALID, Understanding the dynamic determinants of glucose homeostasis and social capability to promote Healthy and active aging - DYNAHEALTH - - H20202015-04-01 - 2019-03-31 - 633595 - VALID, Beyond the Genetics of Addiction - ADDICTION - - EC:FP7:ERC2011-12-01 - 2017-05-31 - 284167 - VALID, Rise of scientific excellence and collaboration for implementing personalised medicine in Estonia - ePerMed - - H20202016-01-01 - 2018-12-31 - 692145 - VALID, University of Oxford, Helmholtz Zentrum München = German Research Center for Environmental Health, Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Università degli Studi di Ferrara = University of Ferrara (UniFE), Université de Lausanne = University of Lausanne (UNIL), Karl-Franzens-Universität Graz, Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki-Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Amsterdam UMC - Amsterdam University Medical Center, Nanyang Technological University [Singapour], Universität zu Lübeck = University of Lübeck [Lübeck], Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Université de Genève = University of Geneva (UNIGE), ANR-18-IBHU-0001,PreciDIAB,PreciDIAB Institute, the holistic approach of personal diabets care(2018), European Project: 633595,H2020,H2020-PHC-2014-two-stage,DYNAHEALTH(2015), European Project: 284167,EC:FP7:ERC,ERC-2011-StG_20101124,ADDICTION(2011), European Project: 692145,H2020,H2020-TWINN-2015,ePerMed(2016), Biological Psychology, APH - Health Behaviors & Chronic Diseases, APH - Personalized Medicine, Functional Genomics, APH - Mental Health, Sociology and Social Gerontology, APH - Methodology, Hottenga, Jouke- Jan [0000-0002-5668-2368], Bouatia-Naji, Nabila [0000-0001-5424-2134], Jansen, Rick [0000-0002-3333-6737], Min, Josine L. [0000-0003-4456-9824], Faggian, Alessia [0000-0002-3799-9722], Bonnefond, Amélie [0000-0001-9976-3005], Isaacs, Aaron [0000-0001-5037-4834], Willems, Sara M. [0000-0002-6803-3007], Navarro, Pau [0000-0001-5576-8584], Jackson, Anne U. [0000-0002-9672-2547], Bielak, Lawrence F. [0000-0002-3443-8030], Saxena, Richa [0000-0003-2233-1065], Smith, Albert V. [0000-0003-1942-5845], Verweij, Niek [0000-0002-4303-7685], Goel, Anuj [0000-0003-2307-4021], Johnson, Paul C. D. [0000-0001-6663-7520], Strawbridge, Rona J. [0000-0001-8506-3585], Fall, Tove [0000-0003-2071-5866], Fraser, Ross M. [0000-0003-0488-2592], Kanoni, Stavroula [0000-0002-1691-9615], Giedraitis, Vilmantas [0000-0003-3423-2021], Kleber, Marcus E. [0000-0003-0663-7275], Müller-Nurasyid, Martina [0000-0003-3793-5910], Luan, Jian’an [0000-0003-3137-6337], Sanna, Serena [0000-0002-3768-1749], Nolte, Ilja M. [0000-0001-5047-4077], Zemunik, Tatijana [0000-0001-8120-2891], Kovacs, Peter [0000-0002-0290-5423], Wild, Sarah H. [0000-0001-7824-2569], McLachlan, Stela [0000-0003-0480-6143], Egan, Josephine [0000-0002-8945-0053], Hicks, Andrew A. [0000-0001-6320-0411], Thorand, Barbara [0000-0002-8416-6440], Hingorani, Aroon [0000-0001-8365-0081], Kivimaki, Mika [0000-0002-4699-5627], Koistinen, Heikki A. [0000-0001-7870-070X], Bakker, Stephan J. L. [0000-0003-3356-6791], Palmer, Colin N. A. [0000-0002-6415-6560], Jukema, J. Wouter [0000-0002-3246-8359], Sattar, Naveed [0000-0002-1604-2593], Snieder, Harold [0000-0003-1949-2298], Magnusson, Patrik K. [0000-0002-7315-7899], Blüher, Matthias [0000-0003-0208-2065], Wolffenbuttel, Bruce H. R. [0000-0001-9262-6921], Abecasis, Goncalo R. [0000-0003-1509-1825], Meigs, James B. [0000-0002-2439-2657], Wilson, James F. [0000-0001-5751-9178], Schwarz, Peter E. H. [0000-0001-6317-7880], Boehm, Bernhard O. [0000-0002-2706-7710], Metspalu, Andres [0000-0002-3718-796X], Deloukas, Panos [0000-0001-9251-070X], Körner, Antje [0000-0001-6001-0356], Wareham, Nicholas J. [0000-0003-1422-2993], Langenberg, Claudia [0000-0002-5017-7344], Männistö, Satu [0000-0002-8668-3046], Franks, Paul W. [0000-0002-0520-7604], Hayward, Caroline [0000-0002-9405-9550], Vitart, Veronique [0000-0002-4991-3797], Kaprio, Jaakko [0000-0002-3716-2455], Visvikis-Siest, Sophie [0000-0001-8104-8425], Altshuler, David [0000-0002-7250-4107], Rudan, Igor [0000-0001-6993-6884], van Duijn, Cornelia M. [0000-0002-2374-9204], Pramstaller, Peter P. [0000-0002-9831-8302], Boehnke, Michael [0000-0002-6442-7754], Frayling, Timothy M. [0000-0001-8362-2603], Peyser, Patricia A. [0000-0002-9717-8459], Harst, Pim van der [0000-0002-2713-686X], Smith, George Davey [0000-0002-1407-8314], Forouhi, Nita G. [0000-0002-5041-248X], Loos, Ruth J. F. [0000-0002-8532-5087], Salomaa, Veikko [0000-0001-7563-5324], Soranzo, Nicole [0000-0003-1095-3852], Boomsma, Dorret I. [0000-0002-7099-7972], Groop, Leif [0000-0002-0187-3263], Tuomi, Tiinamaija [0000-0002-8306-6202], Munroe, Patricia B. [0000-0002-4176-2947], Gudnason, Vilmundur [0000-0001-5696-0084], Lecoeur, Cecile [0000-0003-0075-6417], Jarvelin, Marjo-Riitta [0000-0002-2149-0630], Stefansson, Kari [0000-0003-1676-864X], Dermitzakis, Emmanouil T. [0000-0002-9302-6490], Lindgren, Cecilia M. [0000-0002-4903-9374], Froguel, Philippe [0000-0003-2972-0784], Kaakinen, Marika A. [0000-0002-9228-0462], Watanabe, Richard M. [0000-0003-1015-0531], Ingelsson, Erik [0000-0003-2256-6972], Dupuis, Josée [0000-0003-2871-3603], Barroso, Inês [0000-0001-5800-4520], Apollo - University of Cambridge Repository, Epidemiology, University Hospital Mannheim | Universitätsmedizin Mannheim, National Research Council of Italy | Consiglio Nazionale delle Ricerche (CNR), Universität Leipzig, Universiteit Leiden, Universität Heidelberg [Heidelberg] = Heidelberg University, Karl-Franzens-Universität [Graz, Autriche], Psychiatry, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, General practice, APH - Digital Health, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Center for Liver, Digestive and Metabolic Diseases (CLDM), Value, Affordability and Sustainability (VALUE), Cardiovascular Centre (CVC), Hottenga, Jouke-Jan [0000-0002-5668-2368], Min, Josine L [0000-0003-4456-9824], Willems, Sara M [0000-0002-6803-3007], Jackson, Anne U [0000-0002-9672-2547], Bielak, Lawrence F [0000-0002-3443-8030], Smith, Albert V [0000-0003-1942-5845], Johnson, Paul CD [0000-0001-6663-7520], Strawbridge, Rona J [0000-0001-8506-3585], Fraser, Ross M [0000-0003-0488-2592], Kleber, Marcus E [0000-0003-0663-7275], Luan, Jian'an [0000-0003-3137-6337], Nolte, Ilja M [0000-0001-5047-4077], Wild, Sarah H [0000-0001-7824-2569], Hicks, Andrew A [0000-0001-6320-0411], Koistinen, Heikki A [0000-0001-7870-070X], Bakker, Stephan JL [0000-0003-3356-6791], Palmer, Colin NA [0000-0002-6415-6560], Jukema, J Wouter [0000-0002-3246-8359], Magnusson, Patrik K [0000-0002-7315-7899], Wolffenbuttel, Bruce HR [0000-0001-9262-6921], Abecasis, Goncalo R [0000-0003-1509-1825], Meigs, James B [0000-0002-2439-2657], Wilson, James F [0000-0001-5751-9178], Schwarz, Peter EH [0000-0001-6317-7880], Boehm, Bernhard O [0000-0002-2706-7710], Wareham, Nicholas J [0000-0003-1422-2993], Franks, Paul W [0000-0002-0520-7604], van Duijn, Cornelia M [0000-0002-2374-9204], Pramstaller, Peter P [0000-0002-9831-8302], Frayling, Timothy M [0000-0001-8362-2603], Peyser, Patricia A [0000-0002-9717-8459], Forouhi, Nita G [0000-0002-5041-248X], Loos, Ruth JF [0000-0002-8532-5087], Boomsma, Dorret I [0000-0002-7099-7972], Munroe, Patricia B [0000-0002-4176-2947], Dermitzakis, Emmanouil T [0000-0002-9302-6490], Lindgren, Cecilia M [0000-0002-4903-9374], Kaakinen, Marika A [0000-0002-9228-0462], Watanabe, Richard M [0000-0003-1015-0531], Tampere University, Tays Research Services, Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), Fysiologie, RS: FHML MaCSBio, and RS: Carim - B01 Blood proteins & engineering
- Subjects
Male ,Anorexia Nervosa ,medicine.medical_treatment ,45/43 ,Insulin Resistance/genetics ,SUSCEPTIBILITY ,Quantitative trait ,Impaired glucose tolerance ,0302 clinical medicine ,Architecture ,LS2_1 ,IMPUTATION ,Insulin ,ComputingMilieux_MISCELLANEOUS ,Fasting ,Publisher Correction ,3. Good health ,[SDV] Life Sciences [q-bio] ,Kruppel-Like Transcription Factors/blood ,Endokrinologi och diabetes ,Science & Technology - Other Topics ,Adult ,Blood Glucose ,European Continental Ancestry Group ,Female ,Gene Expression ,Genetic Loci ,Genome-Wide Association Study ,Glucose Intolerance ,Humans ,Insulin Receptor Substrate Proteins ,Insulin Resistance ,Kruppel-Like Transcription Factors ,Middle Aged ,Phenotype ,Sex Characteristics ,Sex Factors ,Waist-Hip Ratio ,Sex characteristics ,medicine.medical_specialty ,Science ,631/208/205/2138 ,Endocrinology and Diabetes ,General Biochemistry, Genetics and Molecular Biology ,White People ,Gender-differences ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,692/53/2421 ,GLYCEMIC TRAITS ,GENOME-WIDE ASSOCIATION ,Glycemic ,GENDER-DIFFERENCES ,Science & Technology ,IDENTIFICATION ,692/699/2743/2815 ,Blood Glucose/metabolism ,Diagnostic markers ,medicine.disease ,Anorexia Nervosa/blood ,030104 developmental biology ,Endocrinology ,Glucose ,Insulin/blood ,Anorexia Nervosa/ethnology ,Anorexia Nervosa/genetics ,Anorexia Nervosa/physiopathology ,Fasting/blood ,Glucose Intolerance/blood ,Glucose Intolerance/ethnology ,Glucose Intolerance/genetics ,Glucose Intolerance/physiopathology ,Insulin Receptor Substrate Proteins/blood ,Insulin Receptor Substrate Proteins/genetics ,Kruppel-Like Transcription Factors/genetics ,0301 basic medicine ,Identification ,[SDV]Life Sciences [q-bio] ,General Physics and Astronomy ,Genome-wide association studies ,Waist–hip ratio ,LS4_5 ,RISK ,ARCHITECTURE ,Multidisciplinary ,article ,Type 2 diabetes ,Multidisciplinary Sciences ,MENDELIAN RANDOMIZATION ,Pre-diabetes ,Medical Genetics ,Risk ,PATHOPHYSIOLOGY ,030209 endocrinology & metabolism ,3121 Internal medicine ,692/163/2743/137/773 ,NO ,Insulin resistance ,Internal medicine ,Diabetes mellitus ,medicine ,Mendelian randomization ,631/208/480 ,Medicinsk genetik ,business.industry ,General Chemistry ,Impaired fasting glucose ,business - Abstract
Differences between sexes contribute to variation in the levels of fasting glucose and insulin. Epidemiological studies established a higher prevalence of impaired fasting glucose in men and impaired glucose tolerance in women, however, the genetic component underlying this phenomenon is not established. We assess sex-dimorphic (73,089/50,404 women and 67,506/47,806 men) and sex-combined (151,188/105,056 individuals) fasting glucose/fasting insulin genetic effects via genome-wide association study meta-analyses in individuals of European descent without diabetes. Here we report sex dimorphism in allelic effects on fasting insulin at IRS1 and ZNF12 loci, the latter showing higher RNA expression in whole blood in women compared to men. We also observe sex-homogeneous effects on fasting glucose at seven novel loci. Fasting insulin in women shows stronger genetic correlations than in men with waist-to-hip ratio and anorexia nervosa. Furthermore, waist-to-hip ratio is causally related to insulin resistance in women, but not in men. These results position dissection of metabolic and glycemic health sex dimorphism as a steppingstone for understanding differences in genetic effects between women and men in related phenotypes., Sex differences in fasting glucose and insulin have been identified, but the genetic loci underlying these differences have not. Here, the authors perform a meta-analysis of genome-wide association studies to detect sex-specific and sex-dimorphic loci associated with fasting glucose and insulin.
- Published
- 2021
6. Long-term prognosis after ST-elevation myocardial infarction in cancer patients
- Author
-
Bart Mertens, J C Heemelaar, M.L. Antoni, E A S Polomski, Joop Jukema, and M.J. Schalij
- Subjects
medicine.medical_specialty ,St elevation myocardial infarction ,business.industry ,Internal medicine ,medicine ,Cardiology ,Cancer ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business ,Term (time) - Abstract
Purpose To assess survival trends after ST-elevation myocardial infarction (STEMI) in patients with a prior cancer diagnosis and to evaluate the drivers of prognosis over a follow-up period of five years. Methods Patients with a known cancer diagnosis, admitted with STEMI between 2004–2014 and treated with primary PCI were recruited from the STEMI-clinical registry of our institution. Detailed information on cancer diagnosis, -stage, and treatment regimen were collected from the institutional and national cancer registry system and all patients were followed prospectively. Results In the 215 included patients the cumulative incidence of all-cause death after 5 years of follow-up was 38.2% (N=61). The cause of death was predominantly malignancy-related (N=29, 47.4% of deaths) and only 9 patients (14.8% of deaths) died of a cardiovascular cause. After correcting for age and sex – a recent cancer diagnosis (10 yr, HR 3.405 [95% CI: 1.552–7.470], p=0.002), distant metastasis at presentation (HR 2.603 [1.236–5.481], p=0.012), ongoing cancer treatment at presentation (HR 1.878 [1.015–3.475], p=0.045) and natural logarithm of maximum creatinine kinase level (HR 1.345 [1.044–1.733], p=0.022) were significant predictors of long-term mortality. While prevalent renal insufficiency showed significant association with all-cause mortality (HR 2.302 [1.289–4.111], p=0.005), other known determinants of long-term prognosis after STEMI – a history of diabetes mellitus (HR 1.250 [0.566–2.761], p=0.581), hypertension (HR 0.623 [0.393–1.085], p=0.150), and culprit vessel left anterior descending artery or left main artery (HR 1.066 [0.641–1.771], p=0.806) were not significantly associated with survival at 5-years follow-up. Conclusion Cancer patients admitted with STEMI have a poor survival with one third of patients died at 5 year follow up. Cancer was the most common cause of death and malignancy-related factors made a significant impact on prognosis, while most of the established cardiovascular determinants of prognosis were not significantly associated with long-term survival. Funding Acknowledgement Type of funding sources: None. Cumulative incidence curve
- Published
- 2021
7. Clinical decision making in frequently encountered anomalous aortic origin of coronary arteries, the impact of IVUS
- Author
-
Monique R.M. Jongbloed, Philippine Kiès, Anastasia D Egorova, Mark G. Hazekamp, Hubert W. Vliegen, Joop Jukema, Diederick B. H. Verheijen, and F. van der Kley
- Subjects
Coronary angiography ,Aorta ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Computed tomography ,Coronary arteries ,medicine.anatomical_structure ,Clinical decision making ,Pulmonary valve ,medicine.artery ,Right coronary artery ,Internal medicine ,medicine ,Cardiology ,Instantaneous wave-free ratio ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction The aim in the diagnostic work-up of patients with an anomalous aortic origin of coronary arteries (AAOCA) is to determine whether the course of the coronary artery is benign or malignant. In patients with AAOCA with an interarterial course the guidelines on diagnostics are concise. Recommended CT-scan imaging does not evaluate stress-induced functional consequences like external compression by the pulmonary artery as the scan is performed in a resting state. Non-invasive ischemia detection techniques often lack sufficient sensitivity. To improve functional stratification, exploration of new diagnostic modalities in the diagnostic workup of AAOCA is mandatory. Purpose The purpose is to explore the potential role of intravascular ultrasound (IVUS) in the diagnostic workup of patients with AAOCA. Methods Nine patients with an anomalous right coronary artery with an interarterial course were analyzed. A cardiologist evaluated the complaints. Anatomical features of the AAOCA were assessed with CT-scan imaging. Further analyses included ischemia detection and coronary angiography. To assess stress-induced ischemia IVUS and invasive measurements – fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) – were performed at rest and during adrenaline-induced stress. A slit-like orifice was classified as a width/length (W/L) ratio of ≤0.50, an oval orifice as 0.51–0.9 and a round orifice as >0.91. Results Potential cardiac complaints were present in seven patients. In 8 (89%) patients CT-images showed an acute angle, in 8 (89%) proximal narrowing and an aortic take-off above the pulmonary valve in 4 (44%). In 7 (78%) patients a slit-like orifice and in two (22%) an oval orifice were observed (table 1). IVUS at rest showed a slit-like orifice in one patient classified as an oval orifice on the CT-images and vice versa in another patient (table 2). The patients classified as an oval orifice with IVUS showed no external compression during adrenaline-induced stress. In 4 (57%) out of 7 patients with an slit-like orifice on IVUS, the width remained unchanged or increased during adrenaline infusion. In 2 patients the width decreased slightly, however, these patients were asymptomatic and no ischemia was detected. In 1 (14%) patient the width remained 1.4mmm and the length increased from 3.2mm to 4.7mm. In this case the vessel ostium was fully engaged with the IVUS catheter, hence, the width could not decrease during adrenaline infusion. This was regarded as external compression. In addition, in this patient ischemia was detected. Conclusion(s) In two (22%) out of 9 patients IVUS gave a better insight of the shape of the orifice than CT. Additionally, the anatomic and functional-dynamic components of compression could be defined with adrenaline-induced stress. Therefore, IVUS can contribute to a better understanding of the functional consequences of the anatomical features and of potential stress-induced external compression. Funding Acknowledgement Type of funding sources: None. Table 1Table 2
- Published
- 2021
8. 2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation: recommendations and critical appraisal from the Dutch ACS and Interventional Cardiology working groups
- Author
-
T.J.F. ten Cate, Yolande Appelman, D. J. van der Heijden, A. de Vos, A. W. J. van ’t Hof, S. Assa, Joop Jukema, P. Woudstra, M. L. J. van der Wielen, P. Damman, Reinier A. Waalewijn, Pieter-Jan Vlaar, Michiel Voskuil, W. Balder, Bastiaan Zwart, J. M. ten Berg, R. S. Hermanides, N. van Royen, Maarten A. Vink, F. Arslan, Jorrit S. Lemkes, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, and MUMC+: MA Med Staf Spec Cardiologie (9)
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,Prasugrel ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,NSTE-ACS ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,PRASUGREL ,medicine ,TICAGRELOR ,030212 general & internal medicine ,Intensive care medicine ,METAANALYSIS ,Interventional cardiology ,Invasive management ,business.industry ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,INVASIVE STRATEGY ,medicine.disease ,Clopidogrel ,Critical appraisal ,NSTEMI ,CLOPIDOGREL ,Dual antiplatelet therapy ,IMMEDIATE ,Cardiology and Cardiovascular Medicine ,business ,Risk assessment ,Working group ,Ticagrelor ,medicine.drug - Abstract
Contains fulltext : 245649.pdf (Publisher’s version ) (Open Access) Recently, the European Society of Cardiology (ESC) has updated its guidelines for the management of patients with acute coronary syndrome (ACS) without ST-segment elevation. The current consensus document of the Dutch ACS working group and the Working Group of Interventional Cardiology of the Netherlands Society of Cardiology aims to put the 2020 ESC Guidelines into the Dutch perspective and to provide practical recommendations for Dutch cardiologists, focusing on antiplatelet therapy, risk assessment and criteria for invasive strategy.
- Published
- 2021
9. Low mitochondrial copy number drives atherogenic cardiovascular disease: evidence from prospective cohort analyses in the UK Biobank combined with Mendelian Randomization
- Author
-
Jiao Luo, Felix Grassmann, D. van Heemst, Joop Jukema, K. Willems van Dijk, S. le Cessie, Raymond Noordam, and Sara Hägg
- Subjects
medicine.medical_specialty ,business.industry ,Hazard ratio ,Single-nucleotide polymorphism ,Disease ,Odds ratio ,medicine.disease ,Coronary artery disease ,Internal medicine ,Mendelian randomization ,medicine ,Prospective cohort study ,business ,Genetic association - Abstract
BackgroundMitochondrial DNA (mtDNA) content might be involved in the risk of cardiovascular disease. We aimed to investigate the association of mtDNA copy number (mtDNA-CN), as a proxy of mtDNA content, and coronary artery disease (CAD) and heart failure (HF) using multivariable adjusted and Mendelian Randomizations (MR) analyses.MethodsMultivariable-adjusted analyses were conducted using Cox-proportional hazard models in 273,619 unrelated European descendants from UK Biobank (UKB). MtDNA-CN in peripheral blood cells was computed based on the weighted intensities of the mitochondrial genome probes. For the two-sample MR analyses, single nucleotide polymorphisms (SNPs) associated with mtDNA-CN were retrieved from genome-wide association studies in UKB. SNP-outcome associations were obtained for CAD from CARDIoGRAMplusC4D, UKB and FinnGen, comprising 902,538 participants (134,759 cases), and for HF from the HERMES consortium and FinnGen, collectively having data on 1,195,531 participants (70,706 cases). MR analyses were performed per database and results were subsequently meta analyzed using fixed-effects models per study.ResultsDuring a median follow-up of 11.8 years, participants in the lowest quintile of mtDNA-CN had higher risk for CAD (hazard ratio [95% CI]: 1.08 [1.03, 1.14]) and HF (hazard ratio [95% CI]: 1.15 [1.05, 1.24]) compared to those in the highest quintile. In MR analyses, the pooled odds ratios of genetically predicted per one-SD decrease in mtDNA were 1.16 (95% CI: 1.05, 1.27) for CAD and 1.00 (95% CI: 0.90, 1.10) for HF, respectively.ConclusionOur findings support a possible causal role of lower mtDNA-CN in higher CAD risk, but not in higher HF risk.
- Published
- 2021
10. Striking rusty-brown neck collars in Ruffs: plumage polymorphism or staining?
- Author
-
Nelli Rönkä, Pavel S. Tomkovich, Theunis Piersma, Yvonne I. Verkuil, Joop Jukema, Jos C.E.W. Hooijmeijer, Conservation Ecology Group, and Piersma group
- Subjects
Calidris pugnax ,Polymorphism (computer science) ,Plumage ,Discoloration ,Iron oxide ,Zoology ,Animal Science and Zoology ,Aquatic Science ,Biology ,Moult ,Ecology, Evolution, Behavior and Systematics ,Staining - Abstract
Among Ruffs Calidris pugnax migrating through the province of Friesland in The Netherlands in spring, some individuals have a remarkably plover-like, rustybrown neck collar. In this paper we explore the frequency of occurrence of this neck collar in 2,395 Ruffs in which the presence or absence was scored in yearround catches in Friesland between 2006 and 2019. Additionally, 49 nesting reeves in northern Finland and 73 skins of females (mostly in breeding plumage) in the Moscow Zoological Museum were checked for neck collars. The rustybrown neck collar was found in 395 Ruffs migrating through The Netherlands in spring. Among birds of known sex, age and morph (n = 2,098), the collar occurred in 14% of females, in 3.5% of faeders, and in 40% of satellite and 20% of independent males. However, among males, the rate dropped to zero by late April after the start of moult of the ruff and tuft feathers, and the occurrence was lower among second-calendar-year males (11%); no age effect was detected among females. Rusty-brown neck collars were rare among breeding females, with no cases in Finland, one possible case in the museum collection and one other case observed in Medusa Bay, north-central Siberia, Russia. The collar was also rare (0.4%) in non-breeding Ruffs caught in The Netherlands between June and February. The likely cause of the neck collar is staining by ferric oxide (Fe2O3) or ferrous oxide (FeO) as collar feathers tested positive for iron, while regular brown feathers tested negative. The presence in spring, but not after moult into the supplemental plumage or later, suggests that the birds acquire the ironbased collar in the wintering areas in West Africa or at stopover sites during northward migration.
- Published
- 2021
11. Publisher Correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability
- Author
-
Stavroula Kanoni, Bakker Sjl., Winkelmann Br, Wieland Kiess, Josée Dupuis, Palmer Cna., James F. Wilson, Schwarz Peh., Maria Dimitriou, Joop Jukema, Sara M. Willems, J L Min, R. Rauramaa, Perry Jrb., Momoko Horikoshi, Timo A. Lakka, Nicole Soranzo, J Kaprio, Niek Verweij, Martina Müller-Nurasyid, Jaana Lindström, Toby Johnson, Olga D. Carlson, Nita G. Forouhi, George Dedoussis, Johnson Pcd., Patrick K.E. Magnusson, Gonçalo R. Abecasis, Ozren Polasek, Wolffenbuttel Bhr., M. I. J. Uusitupa, Longda Jiang, Nancy L. Pedersen, Beate St Pourcain, Erik P A Van Iperen, Iva Miljkovic, Stefania Bandinelli, M. A. Province, Veikko Salomaa, Andrew A. Hicks, Evelin Mihailov, Rick Jansen, James B. Meigs, D Rybin, Peter Kovacs, George Davey Smith, Rona J. Strawbridge, Gudmar Thorleifsson, Meena Kumari, Chiara Scapoli, Christopher J. Groves, Barbara Thorand, T.B. Harris, Ulf de Faire, Inga Prokopenko, Stela McLachlan, Ping An, Anubha Mahajan, L.F. Bielak, Rebecca J. Webster, David Altshuler, Susan Campbell, Bernhard O. Boehm, A. Metspalu, Perttu Salo, D.I. Boomsma, Ilja M. Nolte, Andrea Ganna, Timothy M. Frayling, Pau Navarro, N J Timpson, Kardia Slr., Jeanette M. Stafford, Tõnu Esko, Ulrika Krus, Richa Saxena, Per Eriksson, Peter P. Pramstaller, Anne U. Jackson, V Lagou, Anders Franco-Cereceda, David S. Siscovick, Josephine M. Egan, Loos Rjf., C Gieger, Amanda J. Bennett, Anna Ulrich, Satu Männistö, Mika Kivimäki, Loic Yengo, Caroline Hayward, George Nicholson, C M van Duijn, Anke Tönjes, Nigel W. Rayner, Jose C. Florez, Leif Groop, Valeri Lyssenko, Lyle J. Palmer, Vilmantas Giedraitis, Maria G. Stathopoulou, B. Balkau, Anneli Pouta, Anuj Goel, Pierre Meneton, Serena Sanna, Jesper R. Gådin, Claudia Langenberg, Alessia Faggian, H Grallert, Karen Kapur, Marcus E. Kleber, Philippe Froguel, Boehnke M, Harry Campbell, Anders Hamsten, T. Saaristo, Antigone S. Dimas, Jarvelin M-R., F Karpe, A. Körner, Leena Kinnunen, Markus Perola, Joanne M. Meyer, May E. Montasser, Erik Ingelsson, Naveed Sattar, Yvonne Boettcher, Sirkka Keinänen-Kiukaanniemi, Aaron Isaacs, Gerjan Navis, Ian Ford, Amélie Bonnefond, Reedik Mägi, Tove Fall, Dmitry Shungin, Jenna Price, Igor Rudan, Richard M. Watanabe, Luigi Ferrucci, Jian'an Luan, Harst Pvd., Marika Kaakinen, Tatijana Zemunik, Christian Herder, Shin S-Y., Veronique Vitart, Ross M. Fraser, Alan R. Shuldiner, Panagiotis Deloukas, C. Lecoeur, Letizia Marullo, Kari Stefansson, Lars Lind, Winfried März, L Zudina, Aroon D. Hingorani, Gonneke Willemsen, de Geus Ejcn., Albert V. Smith, Jeffery R. O'Connell, Yongmei Liu, James S. Pankow, Sarah H. Wild, Patricia B. Munroe, Patricia A. Peyser, Nicholas J. Wareham, Tiinamaija Tuomi, Nicholas D. Hastie, Markku Laakso, Albert Hofman, J. Tuomilehto, Emmanouil T. Dermitzakis, Thomas Illig, Tomohiro Tanaka, Cecilia M. Lindgren, Sarin A-P., Alex S. F. Doney, Najaf Amin, Hugh Watkins, Johanna Kuusisto, Andrew P. Morris, Richard N. Bergman, Mark I. McCarthy, Nabila Bouatia-Naji, Günther Silbernagel, João Fadista, Harold Snieder, Ins Barroso, Michael Stumvoll, B.W.J.H. Penninx, M Blüher, Stefan R Bornstein, Laura J. Rasmussen-Torvik, Alan F. Wright, Peter Vollenweider, G K Hovingh, Heikki A. Koistinen, Sophie Visvikis-Siest, Vilmundur Gudnason, Eric Boerwinkle, Hottenga J-J., Guo Li, Paul W. Franks, Université de Lille, Centre de recherche en épidémiologie et santé des populations (CESP), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
- Subjects
Genetics ,Multidisciplinary ,Science ,Insulin ,medicine.medical_treatment ,General Physics and Astronomy ,Diagnostic marker ,Genome-wide association study ,General Chemistry ,Type 2 diabetes ,Quantitative trait locus ,Biology ,medicine.disease ,GeneralLiterature_MISCELLANEOUS ,General Biochemistry, Genetics and Molecular Biology ,Fasting glucose ,Sexual dimorphism ,Pre diabetes ,[SDU]Sciences of the Universe [physics] ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,medicine - Abstract
The original version of this Article contained an error in Fig. 2, in which panels a and b were inadvertently swapped. This has now been corrected in the PDF and HTML versions of the Article.
- Published
- 2021
12. Classical cardiovascular risk factors and secondary major coronary events: A Mendelian randomization study in the UK biobank population
- Author
-
T.A. Brochard, Jacobijn Gussekloo, Joop Jukema, Y.M. Drewes, S. Trompet, Simon P. Mooijaart, Raymond Noordam, and G.C. Verwoert
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Internal medicine ,Population ,Cardiovascular risk factors ,Mendelian randomization ,medicine ,Cardiology and Cardiovascular Medicine ,education ,business ,Biobank - Published
- 2021
13. Differential insulin sensitivity of NMR-based metabolomic measures in a two-step hyperinsulinemic euglycemic clamp study
- Author
-
Carolien A. Wijsman, Raymond Noordam, P.E. Slagboom, Maarten Pieter Rozing, Marian Beekman, K. Willems van Dijk, Wei Wang, Simon P. Mooijaart, and Joop Jukema
- Subjects
medicine.medical_specialty ,Metabolomics ,Endocrinology ,Clamp ,Chemistry ,Internal medicine ,Two step ,medicine ,Insulin sensitivity ,Cardiology and Cardiovascular Medicine ,Differential (mathematics) - Published
- 2021
14. Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial
- Author
-
Stephen D. Wiviott, Tiziano Moccetti, Pierre Deharo, Charles V. Pollack, Joop Jukema, Yedid Elbez, Philippe Gabriel Steg, Shamir R. Mehta, Thomas Cuisset, Andrejs Erglis, Gregory Ducrocq, Sunil V. Rao, Christoph Bode, Marc Cohen, University of Zurich, Steg, P G, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département d'Anatomo-Pathologie [Hôpital Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Freiburg [Freiburg], Harvard Medical School [Boston] (HMS), Rutgers New Jersey Medical School (NJMS), Rutgers University System (Rutgers), Department of Computing and Software (McMaster University), McMaster University [Hamilton, Ontario], Jefferson (Philadelphia University + Thomas Jefferson University), Duke University Medical Center, Leiden University Medical Center (LUMC), University of Latvia (LU), Fondazione Cardiocentro Ticino, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM), Royal Brompton Hospital, CCSD, Accord Elsevier, and Universiteit Leiden
- Subjects
medicine.medical_specialty ,Blood transfusion ,Anemia ,medicine.medical_treatment ,percutaneous coronary intervention ,Eptifibatide ,Hemorrhage ,610 Medicine & health ,percurancous coronary intervention ,030204 cardiovascular system & hematology ,Otamixaban ,11171 Cardiocentro Ticino ,2705 Cardiology and Cardiovascular Medicine ,law.invention ,03 medical and health sciences ,Coronary artery bypass surgery ,chemistry.chemical_compound ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Acute Coronary Syndrome ,Non ST elevation Myocardial Infarction ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,3. Good health ,Treatment Outcome ,chemistry ,Cardiology and Cardiovascular Medicine ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,medicine.drug - Abstract
Background: The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI).Methods: The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a timevarying covariate. The primary ischemic outcome was the composite of all-cause death or MI within 180 days of randomization. Subgroup analyses were performed according to pre-transfusion hemoglobin nadir and bleeding status.Results: 12,547 patients were enrolled. Among these, blood transfusion was used in 489 (3.9%) patients. Patients who received transfusion had a higher rate of death or MI (29.9% vs. 8.1%, p 9.0 g/dl (HR 4.01; p-interaction 9.0g/dl. This suggests possible harm of transfusion in those groups. (C) 2020 Elsevier B.V. All rights reserved.
- Published
- 2020
15. Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial
- Author
-
Robert A. Harrington, Vera Bittner, Harvey D. White, G G Schwartz, Michael Szarek, Joop Jukema, Rafael Diaz, Qian H Li, Deepak L. Bhatt, Andreas M. Zeiher, P G Steg, Yong-Un Kim, Shaun G. Goodman, and Garen Manvelian
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Low density lipoprotein cholesterol ,medicine.disease ,Gastroenterology ,Blood pressure ,Pharmacotherapy ,Diabetes mellitus ,Internal medicine ,Heart failure ,Propensity score matching ,medicine ,Cardiology and Cardiovascular Medicine ,business ,Alirocumab - Abstract
Background New ESC/EAS guidelines advise a low-density lipoprotein cholesterol (LDL-C) target level Aim To overcome these limitations, we performed a propensity score-matching (PSM) analysis of the ODYSSEY OUTCOMES trial, which compared the PCSK9 inhibitor alirocumab with placebo in 18,924 patients with recent ACS. Methods Patients on alirocumab were classified in 1 of 3 pre-specified categories according to Month 4 LDL-C 50 mg/dL (n=2197). Within each category, MACE after Month 4 was compared with patients on placebo using 1:1 PSM on demographic, clinical, and adherence variables. Because the trial design involved blinded substitution of placebo for alirocumab when consecutive LDL-C levels were Results Patients in the three achieved LDL-C categories of the alirocumab group differed by baseline age, sex, geographic region; history of diabetes, smoking, peripheral artery disease, cerebrovascular disease, coronary revascularization, heart failure, obstructive pulmonary disease, or malignancy; type of index ACS event; baseline LDL-C, lipoprotein(a), estimated glomerular filtration rate, body mass index, systolic blood pressure; use of intensive statin therapy; and adherence with study medication. After PSM, patients in each LDL-C category on alirocumab were well matched to patients on placebo for these characteristics. Treatment hazard ratios (HRs) for MACE (Figure) were similar in those with achieved LDL-C 50 mg/dL achieved less benefit. Patients who achieved consecutive LDL-C levels Conclusion After accounting for differences in baseline characteristics and adherence, reduction in risk of MACE with alirocumab was similar in patients who achieved LDL-C Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Sanofi and Regeneron Pharmaceuticals, Inc
- Published
- 2020
16. The association between leptin concentration and blood coagulation
- Author
-
F. R. Rosendaal, Roelof A.J. Smit, Suzanne C. Cannegieter, Willem M. Lijfering, D.T.P. Buis, Joop Jukema, R. de Mutsert, and Tim Christen
- Subjects
Male ,Leptin ,medicine.medical_specialty ,Blood coagulation factors ,Population ,Adipose tissue ,030204 cardiovascular system & hematology ,Fibrinogen ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Venous thrombosis ,Medicine ,Humans ,Platelet ,Platelet activation ,Obesity ,Mean platelet volume ,education ,Blood Coagulation ,Netherlands ,education.field_of_study ,business.industry ,Platelet Distribution Width ,Hematology ,Middle Aged ,Endocrinology ,Cross-Sectional Studies ,030220 oncology & carcinogenesis ,Cohort studies ,Female ,business ,medicine.drug - Abstract
Background The adipocyte-derived hormone leptin has been associated with altered blood coagulation in in vitro studies. However, it is unclear whether this association is relevant in vivo and to what extent this association is influenced by total body fat. Therefore, we aimed to examine the association between serum leptin and blood coagulation while taking total body fat into account in a population-based cohort study. Methods We performed a cross-sectional analysis with baseline measurements of 5797 participants of the Netherlands Epidemiology of Obesity (NEO) study, a population-based cohort of middle-aged men and women. We examined associations between serum leptin concentration and coagulation factor concentrations and parameters of platelet activation in linear regression analyses. All analyses were adjusted for multiple covariates, including total body fat. Results In multivariable adjusted analyses a 1 μg/L higher serum leptin concentration was associated with a 0.22 IU/dL (95% CI: 0.11, 0.32) higher FVIII concentration and a 0.20 IU/dL (95% CI: 0.14, 0.27) higher FIX concentration (3.5 IU/dL FVIII and 3.2 IU/dL FIX per SD leptin). Serum leptin concentration was not associated with FXI, fibrinogen, platelet count, mean platelet volume and platelet distribution width in multivariable adjusted analyses. Discussion This study showed that serum leptin concentration was associated with higher concentrations of FVIII and FIX in an observational study, which could be clinically relevant.
- Published
- 2020
17. Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry
- Author
-
Xiaohui Li, James D. Stewart, Rikje Ruiter, Yongmei Liu, Joop Jukema, Donna K. Arnett, Leslie A. Lange, Daniel S. Evans, Jerome I. Rotter, Solomon K. Musani, Susan R. Heckbert, Christy L. Avery, L. de las Fuentes, D. C. Rao, C E de Keyser, Steve Cummings, L. A. Cupples, Kerri L. Wiggins, Y-Di Chen, David J. Stott, Vilmundur Gudnason, Ulrich Broeckel, Yun J. Sung, T.B. Harris, B. H. Stricker, J. C. Bis, M. A. Ikram, Kent D. Taylor, Traci M. Bartz, Fangui Sun, Nona Sotoodehnia, Nicholas L. Smith, Colleen M. Sitlani, L. J. Launer, Eric A. Whitsel, Alexander P. Reiner, A.G. Uitterlinden, Karen Schwander, Xuejiang Guo, Adolfo Correa, Hanfei Xu, Albert V. Smith, Til Stürmer, James S. Floyd, James G. Wilson, Ramachandran S. Vasan, Evan L. Busch, Bruce M. Psaty, Stella Trompet, Ian Ford, and Epidemiology
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,European Continental Ancestry Group ,Blood lipids ,Locus (genetics) ,Disease ,Cardiovascular ,030226 pharmacology & pharmacy ,White People ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Genetics ,medicine ,2.1 Biological and endogenous factors ,Humans ,Pharmacology & Pharmacy ,Aetiology ,Diuretics ,BAALC ,African Americans ,Pharmacology ,business.industry ,Cholesterol ,Human Genome ,Genetic Variation ,Pharmacology and Pharmaceutical Sciences ,medicine.disease ,R1 ,Lipids ,Black or African American ,Heart Disease ,Good Health and Well Being ,030104 developmental biology ,Endocrinology ,chemistry ,Heart failure ,Meta-analysis ,Hypertension ,Molecular Medicine ,Diuretic ,business ,Genome-Wide Association Study - Abstract
Hypertension (HTN) is a significant risk factor for cardiovascular morbidity and mortality. Metabolic abnormalities, including adverse cholesterol and triglycerides (TG) profiles, are frequent comorbid findings with HTN and contribute to cardiovascular disease. Diuretics, which are used to treat HTN and heart failure, have been associated with worsening of fasting lipid concentrations. Genome-wide meta-analyses with 39,710 European-ancestry (EA) individuals and 9925 African-ancestry (AA) individuals were performed to identify genetic variants that modify the effect of loop or thiazide diuretic use on blood lipid concentrations. Both longitudinal and cross sectional data were used to compute cohort-specific interaction results, which were then combined through meta-analysis in each ancestry. These ancestry-specific results were further combined through trans-ancestry meta-analysis. Analysis of EA data identified two genome-wide significant (p
- Published
- 2020
18. Indications for an early invasive strategy in NSTE-ACS patients
- Author
-
F. Arslan, P. Damman, Johannes Waltenberger, A. H. Liem, Yolande Appelman, R. J. de Winter, J. M. ten Berg, A. W. J. van ’t Hof, Joop Jukema, P. A. L. Tonino, Bastiaan Zwart, ACS - Atherosclerosis & ischemic syndromes, Cardiology, ACS - Heart failure & arrhythmias, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and ACS - Microcirculation
- Subjects
Coronary angiography ,Invasive strategy ,medicine.medical_specialty ,Acute coronary syndrome ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,030204 cardiovascular system & hematology ,GUIDELINES ,03 medical and health sciences ,0302 clinical medicine ,medicine ,MANAGEMENT ,In patient ,030212 general & internal medicine ,Timing ,Point of View ,METAANALYSIS ,UNSTABLE ANGINA ,Framingham Risk Score ,biology ,business.industry ,ACUTE CORONARY SYNDROMES ,medicine.disease ,Troponin ,3. Good health ,LATE INTERVENTION ,Emergency medicine ,biology.protein ,IMMEDIATE ,Cardiology departments ,Cardiology and Cardiovascular Medicine ,business ,Nste acs - Abstract
Contains fulltext : 220929.pdf (Publisher’s version ) (Open Access) An early invasive strategy in patients who have acute coronary syndrome without ST-elevation (NSTE-ACS) can improve clinical outcome in high-risk subgroups. According to the current guidelines of the European Society of Cardiology (ESC), the majority of NSTE-ACS patients are classified as "high-risk". We propose to prioritise patients with a global registry of acute coronary events (GRACE) risk score >140 over patients with isolated troponin rise or electrocardiographic changes and a GRACE risk score
- Published
- 2020
19. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group
- Author
-
J. M. ten Berg, Joop Jukema, R. J. de Winter, F. Arslan, A. H. Liem, A. W. J. van ’t Hof, Yolande Appelman, P. Damman, L. Bongartz, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.01 - Clinical atrial fibrillation, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, ACS - Heart failure & arrhythmias, and ACS - Amsterdam Cardiovascular Sciences
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,ONLY REVASCULARIZATION ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,education ,PERCUTANEOUS CORONARY INTERVENTION ,METOPROLOL ,030204 cardiovascular system & hematology ,MULTIVESSEL DISEASE ,law.invention ,STEMI ,Special Article ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Randomized controlled trial ,law ,Angioplasty ,Medicine ,ST segment ,In patient ,TICAGRELOR ,030212 general & internal medicine ,Myocardial infarction ,cardiovascular diseases ,ANGIOPLASTY ,THROMBUS ASPIRATION ,health care economics and organizations ,Metoprolol ,NVVC ACS working group statement ,OUTCOMES ,business.industry ,STEMI guidelines ,Percutaneous coronary intervention ,medicine.disease ,RANDOMIZED-TRIAL ,3. Good health ,Emergency medicine ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,medicine.drug - Abstract
On behalf of the Dutch ACS working group, we discuss the most important changes in recommendations in the 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation relevant for both the general and interventional cardiologist.
- Published
- 2018
20. Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology
- Author
-
C M van Duijn, James S. Floyd, Maarit A. Laaksonen, André G. Uitterlinden, Colleen M. Sitlani, Y-Di Chen, H J Lin, Christopher Newton-Cheh, Kent D. Taylor, Albert V. Smith, Til Stürmer, Kari E. North, Peter W. Macfarlane, Dennis O. Mook-Kanamori, Raymond Noordam, Yun Li, Jun Li, Tamar Sofer, Raul Mendez-Giraldez, Adrienne M. Stilp, Cathy C. Laurie, Ian Ford, Christy L. Avery, Stella Trompet, Nona Sotoodehnia, Jeffrey Roach, T.B. Harris, Jennifer A. Brody, Susan R. Heckbert, L. A. Cupples, J. C. Bis, Ruifang Li-Gao, Christopher J. O'Donnell, Vilmundur Gudnason, Robert C. Kaplan, Brendan M. Buckley, R. de Mutsert, Jan A. Kors, Steve Cummings, Elsayed Z. Soliman, Xiaohui Li, Kati Kristiansson, Linda Broer, Alexander P. Reiner, Joop Jukema, Aaron Isaacs, Evan L. Busch, Craig R. Lee, Amanda A. Seyerle, Heather M. Highland, Kathleen F. Kerr, Bruce M. Psaty, Leslie A. Lange, Qing Duan, Veikko Salomaa, Kenneth Rice, James D. Stewart, Stephanie M. Gogarten, E. A. Whitsel, Kirk C. Wilhelmsen, Daniel S. Evans, Yongmei Liu, Bruno H. Stricker, Fangui Sun, Kimmo Porthan, A. Hofman, Gina M. Peloso, L. J. Launer, Kerri L. Wiggins, Melanie D. Napier, Jerome I. Rotter, Frits R. Rosendaal, James G. Wilson, Ramachandran S. Vasan, Kardiologian yksikkö, Department of Medicine, Clinicum, Genetica & Celbiologie, Biochemie, RS: CARIM - R1.01 - Blood proteins & engineering, RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, RS: FHML MaCSBio, Epidemiology, Internal Medicine, Medical Informatics, and Erasmus MC other
- Subjects
Male ,0301 basic medicine ,Influencing antihypertensive response ,Aging ,Sodium Chloride Symporter Inhibitors ,Blood-pressure response ,Gene-environment interactions ,Ethnic populations ,VARIANTS ,Cardiovascular ,Bioinformatics ,Cohort Studies ,Electrocardiography ,Cardiovascular drugs ,Heart Rate ,Polymorphism (computer science) ,HYPERTENSIVE PATIENTS ,Epidemiology ,80 and over ,Ethnicity ,WIDE ASSOCIATION ,Pharmacology & Pharmacy ,Longitudinal Studies ,Aged, 80 and over ,Wide association ,Genomewide association ,Variants ,Single Nucleotide ,Pharmacology and Pharmaceutical Sciences ,Genomics ,Middle Aged ,CARDIOVASCULAR DRUGS ,3. Good health ,317 Pharmacy ,Molecular Medicine ,Female ,Cohort study ,medicine.drug ,Adult ,medicine.medical_specialty ,INFLUENCING ANTIHYPERTENSIVE RESPONSE ,MEDLINE ,UNITED-STATES ,Polymorphism, Single Nucleotide ,QT interval ,Article ,03 medical and health sciences ,BLOOD-PRESSURE RESPONSE ,Genetics ,medicine ,Humans ,Polymorphism ,Thiazide ,Hypertensive patients ,Aged ,Pharmacology ,Selection bias ,SELECTION BIAS ,business.industry ,Human Genome ,R1 ,GENE-ENVIRONMENT INTERACTIONS ,United States ,030104 developmental biology ,Pharmacogenetics ,Pharmacogenomics ,GENOMEWIDE ASSOCIATION ,business - Abstract
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) prolongation, a risk factor for highly fatal and difficult to predict ventricular arrhythmias. We examined whether common single-nucleotide polymorphisms (SNPs) modified the association between thiazide use and QT or its component parts (QRS interval, JT interval) by performing ancestry-specific, transethnic and cross-phenotype genome-wide analyses of European (66%), African American (15%) and Hispanic (19%) populations (N = 78 199), leveraging longitudinal data, incorporating corrected standard errors to account for underestimation of interaction estimate variances and evaluating evidence for pathway enrichment. Although no loci achieved genome-wide significance (P
- Published
- 2018
21. Fatty acid-induced transcriptomic and methylomic changes in T-cells are involved in immunometabolism
- Author
-
S.T. Hilt, Joop Jukema, B.T. Heijmans, L. Sinke, A. Ioan-Facsinay, N.A. Reilly, and Koen F. Dekkers
- Subjects
chemistry.chemical_classification ,Transcriptome ,chemistry ,Biochemistry ,Fatty acid ,Cardiology and Cardiovascular Medicine - Published
- 2021
22. Investigating the relationships between unfavorable sleep and metabolomic traits: Evidence from multi-cohort multivariable regression and mendelian randomization analyses
- Author
-
Gonneke Willemsen, Kaitlin H Wade, Marian Beekman, K. Willems van Dijk, Neil Goulding, Ruifang Li-Gao, D.I. Boomsma, M.M. Bos, Constantinos Christodoulides, Naveed Sattar, Nienke Biermasz, R. de Mutsert, M. A. Ikram, L.H. Lumey, Joop Jukema, Debbie A Lawlor, A. Zinderman, Mi Ji Lee, Rebecca C Richmond, Carolien A. Wijsman, I. de Boer, Abbas Dehghan, Ian Ford, Rima Mustafa, Robert A. Schoevers, A. Hofman, L. S. Vijfhuizen, Dennis O. Mook-Kanamori, P.E. Slagboom, Matt J. Neville, Carisha S. Thesing, Annemarie I. Luik, G.C. Verwoert, Fredrik Karpe, A.M. Van Den Maagdenberg, Mohsen Ghanbari, René Pool, Xiang Zhang, F. R. Rosendaal, B.T. Heijmans, Raymond Noordam, Patrick C.N. Rensen, S. Trompet, G.M. Terwindt, Chihua Li, Mariska Bot, B.W.J.H. Penninx, and Simon P. Mooijaart
- Subjects
Oncology ,medicine.medical_specialty ,Metabolomics ,business.industry ,Internal medicine ,Multivariable calculus ,Cohort ,Mendelian randomization ,medicine ,Cardiology and Cardiovascular Medicine ,business ,Sleep in non-human animals ,Regression - Published
- 2021
23. Dietary-derived antioxidants do not decrease the risk of ischemic stroke: A Mendelian randomization study
- Author
-
Joop Jukema, G.C. Verwoert, Jiao Luo, Raymond Noordam, and L.G. Martens
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Ischemic stroke ,Mendelian randomization ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
24. Classical risk factors for primary coronary artery disease from an ageing perspective through Mendelian randomization
- Author
-
Joop Jukema, G.C. Verwoert, K. Willems van Dijk, B. Huiskens, Raymond Noordam, S. Trompet, Simon P. Mooijaart, and S. Jansen
- Subjects
Male ,Aging ,medicine.medical_specialty ,business.industry ,Perspective (graphical) ,Mendelian Randomization Analysis ,medicine.disease ,Coronary artery disease ,Risk factors ,Mendelian Randomization ,Ageing ,LDL cholesterol ,Mendelian randomization ,medicine ,Humans ,Female ,Original Article ,Geriatrics and Gerontology ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Genome-Wide Association Study - Abstract
The significance of classical risk factors in coronary artery disease (CAD) remains unclear in older age due to possible changes in underlying disease pathologies. Therefore, we conducted Mendelian Randomization approaches to investigate the causal relationship between classical risk factors and primary CAD in different age groups. A Mendelian Randomization study was conducted in European-ethnicity individuals from the UK Biobank population. Analyses were performed using data of 22,313 CAD cases (71.6% men) and 407,920 controls (44.5% men). Using logistic regression analyses, we investigated the associations between standardized genetic risk score and primary CAD stratified by age of diagnosis. In addition, feature importance and model accuracy were assessed in different age groups to evaluate predictive power of the genetic risk scores with increasing age. We found age-dependent associations for all classical CAD risk factors. Notably, body mass index (OR 1.22 diagnosis 70 years), blood pressure (OR 1.12 70 years), LDL cholesterol (OR 1.16 70 years), and triglyceride levels (OR 1.11 70 years). In line with the Mendelian Randomization analyses, model accuracy and feature importance of the classical risk factors decreased with increasing age of diagnosis. Causal determinants for primary CAD are age dependent with classical CAD risk factors attenuating in relation with primary CAD with increasing age. These results question the need for (some) currently applied cardiovascular disease risk reducing interventions at older age. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-021-00498-9.
- Published
- 2021
25. Accuracy and reproducibility of fast fractional flow reserve computation from invasive coronary angiography
- Author
-
José M. Montero-Cabezas, Joop Jukema, F. van der Kley, Aukelien C. Dimitriu-Leen, Jeff M. Smit, A R Van Rosendael, J.H.C. Reiber, J.J. Bax, Gerhard Koning, and Arthur J.H.A. Scholte
- Subjects
Male ,medicine.medical_specialty ,Adenosine ,Vasodilator Agents ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Hyperemia ,Coronary Artery Disease ,Fractional flow reserve ,Computational fluid dynamics ,030204 cardiovascular system & hematology ,Coronary Angiography ,Severity of Illness Index ,03 medical and health sciences ,Imaging, Three-Dimensional ,0302 clinical medicine ,Predictive Value of Tests ,Quantitative coronary angiography ,parasitic diseases ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,030212 general & internal medicine ,Myocardial infarction ,Cardiac imaging ,Aged ,Observer Variation ,Original Paper ,Reproducibility ,business.industry ,Coronary Stenosis ,Models, Cardiovascular ,Reproducibility of Results ,Percutaneous coronary intervention ,Thrombolysis ,Middle Aged ,medicine.disease ,Coronary Vessels ,Fractional Flow Reserve, Myocardial ,Conventional PCI ,Radiographic Image Interpretation, Computer-Assisted ,Female ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,TIMI - Abstract
Contains fulltext : 182860.pdf (Publisher’s version ) (Open Access) Fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) is associated with favourable outcome compared with revascularization based on angiographic stenosis severity alone. The feasibility of the new image-based quantitative flow ratio (QFR) assessed from 3D quantitative coronary angiography (QCA) and thrombolysis in myocardial infarction (TIMI) frame count using three different flow models has been reported recently. The aim of the current study was to assess the accuracy, and in particular, the reproducibility of these three QFR techniques when compared with invasive FFR. QFR was derived (1) from adenosine induced hyperaemic coronary angiography images (adenosine-flow QFR [aQFR]), (2) from non-hyperemic images (contrast-flow QFR [cQFR]) and (3) using a fixed empiric hyperaemic flow [fixed-flow QFR (fQFR)]. The three QFR values were calculated in 17 patients who prospectively underwent invasive FFR measurement in 20 vessels. Two independent observers performed the QFR analyses. Mean difference, standard deviation and 95% limits of agreement (LOA) between invasive FFR and aQFR, cQFR and fQFR for observer 1 were: 0.01 +/- 0.04 (95% LOA: -0.07; 0.10), 0.01 +/- 0.05 (95% LOA: -0.08; 0.10), 0.01 +/- 0.04 (95% LOA: -0.06; 0.08) and for observer 2: 0.00 +/- 0.03 (95% LOA: -0.06; 0.07), -0.01 +/- 0.03 (95% LOA: -0.07; 0.05), 0.00 +/- 0.03 (95% LOA: -0.06; 0.05). Values between the 2 observers were (to assess reproducibility) for aQFR: 0.01 +/- 0.04 (95% LOA: -0.07; 0.09), for cQFR: 0.02 +/- 0.04 (95% LOA: -0.06; 0.09) and for fQFR: 0.01 +/- 0.05 (95% LOA: -0.07; 0.10). In a small number of patients we showed good accuracy of three QFR techniques (aQFR, cQFR and fQFR) to predict invasive FFR. Furthermore, good inter-observer agreement of the QFR values was observed between two independent observers.
- Published
- 2017
26. Pathophysiology and treatment of atherosclerosis
- Author
-
Mathijs C. Bodde, Joop Jukema, and S. C. Bergheanu
- Subjects
medicine.medical_specialty ,Lipoprotein modification ,Review Article ,030204 cardiovascular system & hematology ,Bioinformatics ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Medicine ,030212 general & internal medicine ,Hypercholesterolaemia ,Lipoprotein cholesterol ,Future perspective ,business.industry ,Low-density lipoprotein ,Statins ,Atherosclerotic disease ,Atherosclerosis ,Cardiovascular disease ,Pathophysiology ,Clinical trial ,Endocrinology ,chemistry ,lipids (amino acids, peptides, and proteins) ,Cardiology and Cardiovascular Medicine ,business ,Proprotein convertase subtilisin/kexin type-9 ,Lipoprotein - Abstract
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications. In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).
- Published
- 2017
27. PCSK9 inhibition in high-risk patients
- Author
-
Joop Jukema, Laurien E Zijlstra, and Simon P. Mooijaart
- Subjects
Aging ,medicine.medical_specialty ,High risk patients ,business.industry ,Anticholesteremic Agents ,PCSK9 ,PCSK9 Inhibitors ,PCSK9 inhibiting ,MEDLINE ,Cell Biology ,Atherosclerosis ,older patients ,lipid-lowering ,Editorial ,plaque burden ,Older patients ,cardiovascular disease ,Internal medicine ,medicine ,Humans ,Lipid lowering ,business ,Biomarkers ,Aged - Published
- 2019
28. Myocardial infarction patients referred to the primary care physician after 1-year treatment according to a guideline-based protocol have a good prognosis
- Author
-
Mattijs E. Numans, M.J. Schalij, N.E. van Hattem, Mathijs C. Bodde, J.J. Bax, Bart Mertens, Rachid Abou, Joop Jukema, and H.J. van Duijn
- Subjects
medicine.medical_specialty ,Ventricular Ejection Fraction ,030204 cardiovascular system & hematology ,Asymptomatic ,STEMI ,03 medical and health sciences ,left ventricular function ,0302 clinical medicine ,Interquartile range ,general practitioners ,Internal medicine ,medicine ,030212 general & internal medicine ,Myocardial infarction ,cardiovascular diseases ,Proportional hazards model ,business.industry ,practice guideline ,Primary care physician ,Guideline ,medicine.disease ,Original Article ,prognosis ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Mace - Abstract
Introduction Identifying ST-elevation myocardial infarction (STEMI) patients who can be referred back to the general practitioner (GP) can improve patient-tailored care. However, the long-term prognosis of patients who are returned to the care of their GP is unknown. Therefore, the aim of this study was to assess the long-term prognosis of patients referred back to the GP after treatment in accordance with a 1-year institutional guideline-based protocol. Methods All consecutive patients treated between February 2004 up to May 2013 who completed the 1‑year institutional MISSION! Myocardial Infarction (MI) follow-up and who were referred to the GP were evaluated. After 1 year of protocolised monitoring, asymptomatic patients with a left ventricular ejection fraction >45% on echocardiography were referred to the GP. Long-term prognosis was assessed with Kaplan-Meier curves and Cox proportional hazards analysis was used to identify independent predictors for 5‑year all-cause mortality and major adverse cardiovascular events (MACE). Results In total, 922 STEMI patients were included in this study. Mean age was 61.6 ± 11.7 years and 74.4% were male. Median follow-up duration after the 1‑year MISSION! MI follow-up was 4.55 years (interquartile range [IQR] 2.28–5.00). The event-free survival was 93.2%. After multivariable analysis, age, not using an angiotensin-converting enzyme (ACE) inhibitor/angiotensin-II (AT2) antagonist and impaired left ventricular function remained statistically significant predictors for 5‑year all-cause mortality. Kaplan-Meier curves revealed that 80.3% remained event-free for MACE after 5 years. Multivariable predictors for MACE were current smoking and a mitral regurgitation grade ≥2. Conclusion STEMI patients who are referred back to their GP have an excellent prognosis after being treated according to the 1‑year institutional MISSION! MI protocol.
- Published
- 2019
29. P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES
- Author
-
G G Schwartz, Joop Jukema, Chern En Chiang, Robert Pordy, Khalid Yusoff, Qian H Li, Harvey D. White, G. Lecorps, P G Steg, Y Huo, Rafael Diaz, Emil Hagström, Angele Moryusef, Michael Szarek, and Andreas M. Zeiher
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Intracranial Hemorrhages ,medicine.disease ,Low density lipoprotein cholesterol level ,Internal medicine ,Diabetes mellitus ,medicine ,Cardiology ,LDL Cholesterol Lipoproteins ,Cardiology and Cardiovascular Medicine ,business ,PCSK9 Inhibitors ,Alirocumab - Abstract
Background Recent guidelines for cholesterol management recognize uncertainty regarding long-term efficacy and safety of prolonged very low levels of LDL-C on treatment with a PCSK9 inhibitor, including risk of new-onset diabetes. ODYSSEY OUTCOMES used a treat-to-target approach to demonstrate reduction of coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina (MACE) with the PCSK9 inhibitor alirocumab (ALI) vs placebo (PBO) in 18,924 patients with recent acute coronary syndrome and elevated LDL-C despite intensive statin therapy. ALI was blindly adjusted (75 or 150 mg dose) to target LDL-C 0.6–1.3 mmol/L (25–50 mg/dL). To avoid sustained very low LDL-C, blind substitution of PBO for ALI was intended if 2 consecutive LDL-C levels were Purpose We report the efficacy and safety of ALI in patients who reached very low LDL-C (consecutively Methods Of 9462 patients randomized to receive ALI, 730 (7.7%) reached very low LDL-C and had substitution of PBO a median 8.3 months after randomization. Using propensity score matching, they were compared (3:1) with 2152 patients initially assigned to PBO. Propensity score matching was also used to compare the incidence of new-onset diabetes in 525 patients without diabetes at baseline who had very low LDL-C levels on ALI with 1675 matched patients in the PBO group. Neurocognitive events and haemorrhagic stroke were also evaluated in relation to very low LDL-C. Results Overall, ALI reduced the incidence of MACE (9.5% vs 11.1%; HR 0.85, 95% CI 0.78–0.93; P Conclusions The overall efficacy of ALI on cardiovascular outcomes was not diminished by the patients who had blinded substitution of PBO for sustained very low LDL-C. Despite a short duration of active treatment, these patients had fewer MACE than matched controls from the PBO group. No adverse consequence of very low LDL-C was identified. However, because patients with sustained very low LDL-C were switched to PBO, the long-term safety of more prolonged very low LDL-C, including risk of new-onset diabetes, deserves further study. Acknowledgement/Funding Funded by Sanofi and Regeneron Pharmaceuticals
- Published
- 2019
30. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
- Author
-
Michael Szarek, Joop Jukema, Shaun G. Goodman, Zeljko Reiner, Rafael Diaz, Alexander Parkhomenko, Gregory G. Schwartz, Vera Bittner, Robert Pordy, Phillippe Gabriel Steg, Andreas M. Zeiher, Odyssey Outcomes, Marie T. Baccara-Dinet, Qian H Li, Hung-Fat Tse, and Deepak L. Bhatt
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Unstable angina ,Atorvastatin ,Absolute risk reduction ,medicine.disease ,Intensity (physics) ,Pharmacotherapy ,Internal medicine ,medicine ,Cardiology ,Rosuvastatin ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Alirocumab - Abstract
Background Statins are a cornerstone of therapy for coronary heart disease. We describe the effects of alirocumab (ALI) in patients (pts) with recent acute coronary syndrome (ACS) and dyslipidaemia per category of statin use. Methods ODYSSEY OUTCOMES compared ALI with placebo (PBO) in 18,924 pts with recent ACS and dyslipidaemia despite high-intensity/maximum tolerated statin (atorvastatin 40–80 mg/d or rosuvastatin 20–40 mg/d). Lower doses could be used if there were symptoms, laboratory abnormalities, or contraindications with higher doses. In cases of documented intolerance to ≥2 statins, pts could qualify on no statin treatment. Pts were randomized to ALI (75 mg SC Q2W, with possible uptitration to 150 mg Q2W) or PBO. Median follow-up was 2.8 years. Primary endpoint was major adverse cardiovascular events (MACE: CHD death, non-fatal MI, ischaemic stroke, or unstable angina requiring hospitalization). Pts were categorized by statin therapy at baseline: high intensity (88.8%), low or moderate intensity (8.7%), or no statin use (2.4%). In each category we determined the relative (hazard ratio [HR]) and absolute risk reductions (ARR) for MACE with ALI. Results Overall, ALI reduced MACE (HR 0.85, 95% CI 0.78–0.93; P LDL-C values and MACE events All patients High-intensity statin Low-/moderate-intensity statin No statin Interaction P-value N=18,924 (100%) N=16,811 (88.8%) N=1653 (8.7%) N=460 (2.4%) (treatment x statin category) PBO (N=9462) ALI (N=9462) PBO (N=8431) ALI (N=8380) PBO (N=804) ALI (N=849) PBO (N=227) ALI (N=233) LDL-C at baseline, mmol/L, mean (SE)* 2.39 (0.01) 2.39 (0.01) 2.35 (0.01) 2.35 (0.01) 2.41 (0.03) 2.43 (0.03) 3.76 (0.08) 3.82 (0.08) Change in LDL-C from baseline to Month 4, mmol/L, mean (SE) 0.03 (0.01) −1.4 (0.01) 0.03 (0.01) −1.37 (0.01) 0.01 (0.02) −1.47 (0.02) −0.004 (0.06) −2.27 (0.06) Conclusions In ODYSSEY OUTCOMES, patients unable to receive high-intensity statin treatment showed greater ARRs with ALI, consistent with higher baseline LDL-C concentration and greater absolute LDL-C reduction. Patients unable to receive high-intensity statin treatment are an important group to consider for treatment with ALI after ACS. Acknowledgement/Funding Funded by Sanofi and Regeneron Pharmaceuticals
- Published
- 2019
31. Genome-wide association study provides new insights into the genetic architecture and pathogenesis of heart failure
- Author
-
Stefan Gross, Honghuang Lin, Diane T. Smelser, März W, Niek Verweij, Alexander Niessner, Peter M. Visscher, Ruth C. Lovering, Erik Ingelsson, Nicholas L. Smith, Lars Lind, Jerome I. Rotter, Anna Helgadottir, David J. Stott, Michelle L. O'Donoghue, Daniel I. Chasman, Karoline Kuchenbaecker, Morris Ad, Michael W. Nagle, Morris Ap, Steven A. Lubitz, Giedraitis, Abirami Veluchamy, Paul M. Ridker, David J. Carey, Benoit Tyl, Carolina Roselli, Laura M. Yerges-Armstrong, Michael R. Brown, Faiez Zannad, Aroon D. Hingorani, Åsa K. Hedman, Nilesh J. Samani, Daníel F. Guðbjartsson, Maris Teder-Laving, Stephan B. Felix, Christopher Newton-Cheh, Marcus Dörr, Thomas P. Cappola, Daniel I. Swerdlow, Leonard Buckbinder, Xiaosong Wang, Alex S. F. Doney, C. Andersson, Jonathan H. Chung, Joshua D. Backman, Tõnu Esko, Mohsen Ghanbari, Joop Jukema, Ian Ford, Gunnar Engström, Kent D. Taylor, Johan Ärnlöv, P.E Weeke, Kenneth B. Margulies, Peter Svensson, Folkert W. Asselbergs, Lars Køber, Michael V. Holmes, Anders Mälarstig, Chim C. Lang, Krishna G. Aragam, Samuel C. Dudley, Christian Torp-Pedersen, Bruce M. Psaty, Alexander Teumer, John J.V. McMurray, Raul Weiss, Smith Jg, Patrick T. Ellinor, Anjali T. Owens, Ify R. Mordi, G Sveinbjörnsson, Luca A. Lotta, John S. Gottdiener, Christopher M. Haggerty, Christopher P. Nelson, C M Lindgren, Hilma Holm, Michael E. Dunn, Albert Henry, Helen M. Parry, Salomaa, Huilin Xing, Kenneth Rice, Marcus E. Kleber, Spiros Denaxas, Chris Finan, Xu Chen, Unnur Thorsteinsdottir, Naveed Sattar, Bing Yu, Kerri L. Wiggins, Alaa Shalaby, Romaine Spr., Patrik K. E. Magnusson, Adriaan A. Voors, Lumbers Rt, Stella Trompet, Maryam Kavousi, Kari Stefansson, Jian'an Luan, Harry Hemingway, van Setten J, Anubha Mahajan, Olle Melander, Uwe Völker, Peter Almgren, Chaffin, Palmer Cna., Eliana Portilla-Fernandez, Stefan Stender, Markus Perola, Guðmundur Thorgeirsson, Ghazaleh Fatemifar, Teemu J. Niiranen, Nicholas J. Wareham, Andrea Koekemoer, James P. Cook, Jeff Brandimarto, Jian Yang, Mary L. Biggs, Claudia Langenberg, Perttu Salo, Sonia Shah, A.G. Uitterlinden, Mari-Liis Tammesoo, Jemma B. Wilk, Craig L. Hyde, Graciela E. Delgado, van der Harst P, Alanna C. Morrison, Kay-Tee Khaw, Barry London, Rebecca Gutmann, Thomas M. Morgan, Franco Giulianini, Abbas Dehghan, Heather L. Bloom, William A. Chutkow, Dawn M. Waterworth, Ramachandran S. Vasan, Jing Hua Zhao, Morley Mp, and Sahar Ghasemi
- Subjects
2. Zero hunger ,0303 health sciences ,business.industry ,Atrial fibrillation ,Genome-wide association study ,030204 cardiovascular system & hematology ,Quantitative trait locus ,medicine.disease ,Bioinformatics ,Genetic architecture ,3. Good health ,Coronary artery disease ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Heart failure ,medicine ,Mendelian inheritance ,symbols ,business ,030304 developmental biology ,Genetic association - Abstract
Heart failure (HF) is a leading cause of morbidity and mortality worldwide1. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained2–4. We report the largest GWAS meta-analysis of HF to-date, comprising 47,309 cases and 930,014 controls. We identify 12 independent variant associations with HF at 11 genomic loci, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function suggesting shared genetic aetiology. Expression quantitative trait analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homeostasis (BAG3), and cellular senescence (CDKN1A). Using Mendelian randomisation analysis we provide new evidence supporting previously equivocal causal roles for several HF risk factors identified in observational studies, and demonstrate CAD-independent effects for atrial fibrillation, body mass index, hypertension and triglycerides. These findings extend our knowledge of the genes and pathways underlying HF and may inform the development of new therapeutic approaches.
- Published
- 2019
- Full Text
- View/download PDF
32. Predicting biological age based on the BBMRI-NL 1H-NMR metabolomics repository
- Author
-
C.M. van Duijn, Simon P. Mooijaart, J.J.H. Barkey Wolf, Joop Jukema, B.W.J.H. Penninx, Mihai G. Netea, Bbmri-Nl, A. H. Zwinderman, Coen D.A. Stehouwer, Joris Deelen, P. Eline Slagboom, Leen M 't Hart, Marcel J. T. Reinders, H.E.D. Suchiman, D.I. Boomsma, Naveed Sattar, Stella Trompet, Marian Beekman, Ingrid Meulenbelt, Hailiang Mei, Alexandra Zhernakova, I. C. C. van der Horst, Eric Boersma, Folkert W. Asselbergs, M.M.J. van Greevenbroek, Mohammad Arfan Ikram, A.M.J.M. van den Maagdenberg, Morris A. Swertz, Petra J. M. Elders, E. B. van den Akker, Mariska Slofstra, Rob G H H Nelissen, Charlotte E. Teunissen, Margreet Kloppenburg, C.J.H. van der Kallen, W.E. van Spil, Gisela M. Terwindt, Davy Cats, P. van der Harst, Johanna M. Geleijnse, and Cisca Wijmenga
- Subjects
Data access ,Increased risk ,Metabolomics ,Biological age ,Metabolome ,Disease ,Chronological age ,Computational biology ,Biology ,Metabolomics data - Abstract
The blood metabolome incorporates cues from the environment as well as the host’s genetic background, potentially offering a holistic view of an individual’s health status. We have compiled a vast resource of 1H-NMR metabolomics and phenotypic data encompassing over 25,000 samples derived from 26 community and hospital-based cohorts. Using this resource, we constructed a metabolomics-based age predictor (metaboAge) to calculate an individual’s biological age. Exploration in independent cohorts demonstrates that being judged older by one’s metabolome, as compared to one’s chronological age, confers an increased risk on future cardiovascular disease, mortality and functionality in older individuals. A web-based tool for calculating metaboAge (metaboage.researchlumc.nl) allows easy incorporation in other epidemiological studies. Access to data can be requested at bbmri.nl/samples-images-data. In summary, we present a vast resource of metabolomics data and illustrate its merit by constructing a metabolomics-based score for biological age that captures aspects of current and future cardio-metabolic health.
- Published
- 2019
33. Borderline Q-waves in individuals without overt cardiovascular disease: Relations with adiposity, subclinical atherosclerosis and vascular stiffness
- Author
-
F. R. Rosendaal, H.J. Lamb, R. de Mutsert, Theodora W. Elffers, Joop Jukema, Stella Trompet, Arie C. Maan, and Peter W. Macfarlane
- Subjects
Male ,medicine.medical_specialty ,Waist ,Adipose tissue ,Disease ,Pulse Wave Analysis ,030204 cardiovascular system & hematology ,Left ventricular hypertrophy ,Vascular stiffness ,Carotid Intima-Media Thickness ,Risk Assessment ,Electrocardiography ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Borderline Q-waves ,Humans ,Medicine ,Obesity ,Prospective Studies ,030212 general & internal medicine ,Subclinical atherosclerosis ,Pulse wave velocity ,Adiposity ,Aged ,Netherlands ,business.industry ,Incidence ,Middle Aged ,Atherosclerosis ,medicine.disease ,Blood pressure ,Epidemiology of obesity ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Body mass index ,Follow-Up Studies - Abstract
Background: \ud Characteristics and risk factors associated with electrocardiographic borderline Q-waves are not fully elucidated, especially in individuals without overt cardiovascular disease (CVD). Also, the relation of isolated and non-isolated borderline Q-waves with subclinical atherosclerosis and vascular stiffness is unknown.\ud \ud Methods and results: \ud We included 5746 Netherlands Epidemiology of Obesity study participants without overt CVD. Participants were divided in three groups: no Q-waves (93.7%), isolated (4.6%) and non-isolated borderline Q-waves (1.7%). Borderline Q-waves were defined as Minnesota Codes 1.2.x and 1.3.x and non-isolated as ≥1 of abnormal QRS axis, left ventricular hypertrophy or ST/T abnormalities. Several characteristics and measures of body fat were assessed. Vascular stiffness was assessed by pulse wave velocity (PWV) and subclinical atherosclerosis by carotid intima-media thickness (cIMT). Percentage of men, alcohol intake, blood pressure and fasting glucose concentrations were, compared with no Q-waves, higher in the isolated and highest in the non-isolated borderline Q-wave group. Isolated borderline Q-waves were associated with higher body mass index (difference compared with no Q-waves: 1.0 kg/m2; 95%CI: 0.3–1.7; p-value: 0.006), waist circumference (3.4 cm; 1.0–5.8; 0.005), and visceral adipose tissue (21.9 cm2; 7.4–36.3; 0.003) and differences were even larger for non-isolated borderline Q-waves. Compared with no Q-waves, non-isolated borderline Q-waves were associated with higher PWV (1.2 m/s; 0.4–2.0; 0.004) and cIMT (23.4 μm; 3.0–43.8; 0.024), whereas isolated borderline Q-waves were not.\ud \ud Conclusion: \ud Cardiovascular risk factors and measures of body fat, especially abdominal adiposity, were higher in participants with isolated borderline Q-waves, compared with no Q-waves, and highest in the non-isolated borderline Q-wave group. Non-isolated borderline Q-waves were associated with subclinical atherosclerosis and vascular stiffness. Future studies should investigate potential added value of borderline Q-waves in CVD prediction.
- Published
- 2019
34. GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes
- Author
-
Tina Shah, E. C. M. van Leeuwen, Jingjing Liang, Susan M. Ring, Alexander Teumer, P Anugu, Salman M. Tajuddin, Aaron Isaacs, Jorgen Engmann, Marcus Dörr, Kenneth Rice, Anne B. Newman, Sonia Shah, Lenore J. Launer, Diana Kuh, Panos Roussos, P. De Vries, Bo Hedblad, Xiaofeng Zhu, Walter Palmas, John E. Deanfield, Debbie A Lawlor, Ganesh Chauhan, Dennis O. Mook-Kanamori, André G. Uitterlinden, Sudha Seshadri, Ilja M. Nolte, Elmo Mannarino, Daniel H. O'Leary, Susan R. Heckbert, Bogdan Pasaniuc, Solomon K. Musani, Rebecca Hardy, Rainer Malik, Lesca M. Holdt, Lars Lind, Reinhold Schmidt, R. de Mutsert, Aroon D. Hingorani, Riccardo E. Marioni, P. Amouyel, Albert V. Smith, Janne Pott, Eric E. Schadt, Lyytikäinen L-P., Raymond Noordam, Stéphanie Debette, Oscar H. Franco, Vincent Plagnol, Gerardo Heiss, Brenda W.J.H. Penninx, SG Wannamethee, Carl D. Langefeld, Stella Trompet, C.M. van Duijn, Tessel E. Galesloot, Peter K. Joshi, Maryam Kavousi, Juan P. Casas, Joanna M. Wardlaw, P. Giral, Julian Halcox, Björkegren Jlm., U de Faire, Andries J. Smit, Christina L. Wassel, Christopher J. O'Donnell, Matthew Traylor, Uwe Völker, Mika Kivimäki, Jenna Price, Quenna Wong, Chris Finan, Wayne D. Rosamond, Markus Loeffler, Harry Campbell, L Lu, Jerome I. Rotter, Joop Jukema, Karl Gertow, Edith Hofer, Hugh S. Markus, Albert Hofman, Peter H. Whincup, James G. Wilson, Michelle K. Evans, Enzo Grossi, Matthias Sitzer, Martin Dichgans, Oscar L. Rueda-Ochoa, J. C. Bis, Klodian Dhana, Ralph Burkhardt, Harold Snieder, Kiemeney Lalm., Daniel Teupser, A C Morrison, Markus Scholz, Ulf Schminke, Richard W Morris, Meena Kumari, Caroline Dale, Helena Schmidt, Sara Hägg, Niina Pitkänen, Fabrizio Veglia, Donald W. Bowden, Olli T. Raitakari, Joachim Thiery, Anders Hamsten, Muralidharan Sargurupremraj, Hwang S-J., Elena Tremoli, Stela McLachlan, Amanda J. Cox, Kent D. Taylor, Frank Beutner, Henry Völzke, Terho Lehtimäki, Abbas Dehghan, Ruth C. Lovering, Rachael P. Huntley, Mike A. Nalls, Jemma C. Hopewell, Erik Ingelsson, Claudia Giambartolomei, Bruce M. Psaty, Annie Britton, A Seldenrijk, Bengt Sennblad, Olle Melander, J. de Graaf, Adolfo Correa, Fernando Rivadeneira, Oscar Franzén, Laura M. Raffield, Alan B. Zonderman, Rona J. Strawbridge, Thomas W. Winkler, Ian J. Deary, Misa Graff, Wendy S. Post, Andrew Wong, T.B. Harris, Yasaman Saba, Arno Ruusalepp, James F. Wilson, Vilmundur Gudnason, Eric Boerwinkle, Damiano Baldassarre, Cristiano Fava, S.E. Humphries, Sudhir Kurl, Rainer Rauramaa, Christophe Tzourio, Xuejiang Guo, Nora Franceschini, Xiaoling Zhang, Biochemie, RS: FHML MaCSBio, RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, RS: CARIM - R1.01 - Blood proteins & engineering, Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), Vascular Ageing Programme (VAP), Faculty of Medicine (UI), Læknadeild (HÍ), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland, Giambartolomei, Claudia [0000-0003-2786-1225], Huntley, Rachael P [0000-0001-6718-3559], Lovering, Ruth C [0000-0002-9791-0064], Tajuddin, Salman M [0000-0002-7919-8528], Winkler, Thomas W [0000-0003-0292-5421], Nolte, Ilja M [0000-0001-5047-4077], Scholz, Markus [0000-0002-4059-1779], Joshi, Peter K [0000-0002-6361-5059], Isaacs, Aaron [0000-0001-5037-4834], Correa, Adolfo [0000-0002-9501-600X], Teumer, Alexander [0000-0002-8309-094X], Wong, Andrew [0000-0003-2079-4779], Newman, Anne B [0000-0002-0106-1150], Sennblad, Bengt [0000-0002-4360-8003], Baldassarre, Damiano [0000-0002-2766-8882], Kuh, Diana [0000-0001-7386-2857], Schadt, Eric E [0000-0002-7892-8808], Rivadeneira, Fernando [0000-0001-9435-9441], Jukema, J Wouter [0000-0002-3246-8359], Rice, Kenneth [0000-0002-3071-7278], Dhana, Klodian [0000-0002-6397-7009], Dichgans, Martin [0000-0002-0654-387X], Traylor, Matthew [0000-0001-6624-8621], Kivimaki, Mika [0000-0002-4699-5627], Roussos, Panos [0000-0002-4640-6239], Amouyel, Philippe [0000-0001-9088-234X], Burkhardt, Ralph [0000-0003-1924-1202], Morris, Richard W [0000-0001-7240-4563], Hägg, Sara [0000-0002-2452-1500], Lawlor, Deborah A [0000-0002-6793-2262], Wilson, James F [0000-0001-5751-9178], Wardlaw, Joanna M [0000-0002-9812-6642], Lyytikäinen, Leo-Pekka [0000-0002-7200-5455], Gudnason, Vilmundur [0000-0001-5696-0084], Apollo - University of Cambridge Repository, Psychiatry, APH - Mental Health, APH - Digital Health, Epidemiology, Internal Medicine, and Experimental Immunology
- Subjects
0301 basic medicine ,Candidate gene ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,General Physics and Astronomy ,Genome-wide association study ,Coronary Disease ,VARIANTS ,Carotid Intima-Media Thickness ,Coronary artery disease ,Protein-Lysine 6-Oxidase ,Risk Factors ,Medicine ,genetics ,Cardiac and Cardiovascular Systems ,Blóðrásarsjúkdómar ,lcsh:Science ,GENE-PRODUCT ,cardiovascular genetics ,Multidisciplinary ,Kardiologi ,Plaque, Atherosclerotic ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Cardiology ,cardiovascular system ,Medical genetics ,CORONARY-ARTERY-DISEASE ,HEART ,Amino Acid Oxidoreductases ,Erfðarannsóknir ,Medical Genetics ,medicine.medical_specialty ,MEGASTROKE Consortium ,Science ,Quantitative Trait Loci ,ADAMTS9 Protein ,INTEGRATIVE ANALYSIS ,Locus (genetics) ,610 Medicine & health ,Quantitative trait locus ,Polymorphism, Single Nucleotide ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,360 Social problems & social services ,Internal medicine ,MD Multidisciplinary ,Humans ,Erfðafræði ,intima media thickness ,Genetic Predisposition to Disease ,cardiovascular diseases ,GENOME-WIDE ASSOCIATION ,METAANALYSIS ,Genetic association ,Medicinsk genetik ,business.industry ,General Chemistry ,medicine.disease ,030104 developmental biology ,Intima-media thickness ,genome-wide association studies ,quantitative trait loci ,lcsh:Q ,atherosclerosis ,Lod Score ,hjarta ,business ,Genome-Wide Association Study - Abstract
Publisher's version (útgefin grein), Carotid artery intima media thickness (cIMT) and carotid plaque are measures of subclinical atherosclerosis associated with ischemic stroke and coronary heart disease (CHD). Here, we undertake meta-analyses of genome-wide association studies (GWAS) in 71,128 individuals for cIMT, and 48,434 individuals for carotid plaque traits. We identify eight novel susceptibility loci for cIMT, one independent association at the previously-identified PINX1 locus, and one novel locus for carotid plaque. Colocalization analysis with nearby vascular expression quantitative loci (cis-eQTLs) derived from arterial wall and metabolic tissues obtained from patients with CHD identifies candidate genes at two potentially additional loci, ADAMTS9 and LOXL4. LD score regression reveals significant genetic correlations between cIMT and plaque traits, and both cIMT and plaque with CHD, any stroke subtype and ischemic stroke. Our study provides insights into genes and tissue-specific regulatory mechanisms linking atherosclerosis both to its functional genomic origins and its clinical consequences in humans., The work was supported by the following grants: National Institute of Health grants: R21HL123677, R21-HL140385, DK104806-01A1, R01-MD012765-01A1 (NF), National Institutes of Health awards R01HG009120, R01HG006399, U01CA194393, T32NS048004 (CG), the American Heart Association Grant #17POST33350042 (PV), the British Heart Foundation (RG/13/5/30112) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (RCL and RPH), the British Heart Foundation FS/14/55/30806 (JCH), the German Federal Ministry of Education and Research (BMBF) in the context of the e:Med program (e:AtheroSysMed), the DFG as part of the CRC 1123 (B3), and the FP7/2007-2103 European Union project CVgenes@target (grant agreement number Health-F2-2013-601456). We thank Li-Ming Gan for assistance with the STARNET study and Jon White for assistance with UCLEB analyses. Additional acknowledgements are included in Supplementary Note 2.
- Published
- 2018
35. Interplay of circulating leptin and obesity in cognition and cerebral volumes in older adults
- Author
-
Raymond Noordam, Simon P. Mooijaart, Joop Jukema, Behnam Sabayan, Stella Trompet, M.H. Zonneveld, J. van der Grond, and D. van Heemst
- Subjects
Leptin ,Male ,medicine.medical_specialty ,Physiology ,Circulating leptin ,030209 endocrinology & metabolism ,Hippocampus ,Biochemistry ,Body Mass Index ,BMI ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Cognition ,0302 clinical medicine ,Endocrinology ,Cognitive dysfunction ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Obesity ,Prospective cohort study ,Cerebral volumes ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,Middle Aged ,Cardiovascular disease ,medicine.disease ,Magnetic Resonance Imaging ,Cognitive test ,Cardiovascular Diseases ,Older adults ,Female ,business ,Body mass index ,030217 neurology & neurosurgery ,Pravastatin ,Stroop effect ,medicine.drug - Abstract
We aimed to investigate whether circulating leptin and body mass index (BMI) associate independently with cognitive function (decline) and brain volumes using magnetic resonance imaging (MRI) in older individuals at risk of cardiovascular disease. We studied the cross-sectional and longitudinal associations in participants enrolled in the PROSPER study (Prospective Study of Pravastatin in the Elderly at Risk). Cognitive function was tested at baseline and repeated during a mean follow-up time of 3.2 years. Analyses were performed with multivariable (repeated) linear regression models and adjusted for demographics, cardiovascular risk-factors, and stratified by sex. We included 5623 dementia-free participants (52 % female, mean age 75 years) with a mean BMI of 26.9 (SD = 4.1). In a sub-study, 527 participants underwent brain MRI. At baseline, individuals with a BMI > 30 had a worse performance on the Stroop test (beta 5.0 s, 95 %CI 2.6;7.5) and larger volumes of the amygdala (beta 234 mm(3), 95 %CI 3;464) and hippocampus (beta 590 mm(3), 95 %CI 181;999), independent of intracranial volume and serum leptin levels, compared with individuals with the reference BMI (BMI 18-25 kg/m(2)). Per log ng/mL higher serum leptin, independent of BMI, a 135 mm(3) (95 %CI 2;268) higher volume of the amygdala was found, but no association was observed with cognitive tests nor with other brain volumes. Stratification for sex did not materially change the results. Whereas higher BMI associated with worse cognitive function independent of leptin levels, our study provided evidence that leptin and BMI independently associate with amygdala volume suggesting potential distinct biological associations.
- Published
- 2021
36. Treatment variation in stent choice in patients with stable or unstable coronary artery disease
- Author
-
Johannes Waltenberger, Elizabeth A. McClellan, Laura Burgers, Joop Jukema, Imo E. Hoefer, A. C. Stubbs, Marieke A. Hillaert, Nico H.J. Pijls, Sebastiaan Horsman, Gerard Pasterkamp, Johan L. Severens, William K. Redekop, Health Technology Assessment (HTA), Pathology, Cardiovascular Biomechanics, MUMC+: MA Alg Interne Geneeskunde (9), Cardiologie, and Beleid Economie & Organisatie vd Zorg
- Subjects
Bare-metal stent ,medicine.medical_specialty ,medicine.medical_treatment ,Original Article - ICIN ,030204 cardiovascular system & hematology ,SDG 3 – Goede gezondheid en welzijn ,Coronary artery disease ,Percutaneous coronary intervention ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Journal Article ,In patient ,030212 general & internal medicine ,cardiovascular diseases ,business.industry ,Stent ,medicine.disease ,equipment and supplies ,surgical procedures, operative ,Drug-eluting stent ,Treatment variation ,Cardiology ,business ,Cardiology and Cardiovascular Medicine - Abstract
Aim Variations in treatment are the result of differences in demographic and clinical factors (e.g. anatomy), but physician and hospital factors may also contribute to treatment variation. The choice of treatment is considered important since it could lead to differences in long-term outcomes. This study explores the associations with stent choice: i.e. drug-eluting stent (DES) versus bare-metal stents (BMS) for Dutch patients diagnosed with stable or unstable coronary artery disease (CAD). Methods & results Associations with treatment decisions were based on a prospective cohort of 692 patients with stable or unstable CAD. Of those patients, 442 patients were treated with BMS or DES. Multiple logistic regression analyses were performed to identify variables associated with stent choice. Bivariate analyses showed that NYHA class, number of diseased vessels, previous percutaneous coronary intervention, smoking, diabetes, and the treating hospital were associated with stent type. After correcting for other associations the treating hospital remained significantly associated with stent type in the stable CAD population. Conclusions This study showed that several factors were associated with stent choice. While patients generally appear to receive the most optimal stent given their clinical characteristics, stent choice seems partially determined by the treating hospital, which may lead to differences in longterm outcomes.
- Published
- 2016
37. Correction to: Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group
- Author
-
T. F. S. Pustjens, M. L. J. van der Wielen, P. Damman, R. J. de Winter, J. M. ten Berg, Willem R.P. Agema, Yolande Appelman, A. W. J. van ’t Hof, Saman Rasoul, F. Arslan, and Joop Jukema
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,030204 cardiovascular system & hematology ,medicine.disease ,3. Good health ,Coronary arteries ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Internal medicine ,medicine ,Cardiology ,Position paper ,In patient ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
The reference to the term acute coronary syndrome with normal or near-normal (non-obstructive) coronary arteries (ACSNNOCA) from Manolis et al. (2018) was inadvertently omitted to the original published article. Therefore, the following reference should be added to our paper:Manolis AS, Manolis AA, Manolis TA, Melita H. Acute coronary syndromes in patients with angiographically normal or near normal (non-obstructive) coronary arteries. Trends Cardiovasc Med. 2018;28(8):541–51. https://doi.org/10.1016/j.tcm. 2018.05.006. The authors would like to apologise for any inconvenience caused.
- Published
- 2020
38. Publisher Correction: Fuelling conditions at staging sites can mitigate Arctic warming effects in a migratory bird
- Author
-
T. Lee Tibbitts, Anatoly Gavrilov, Jan A. van Gils, Anatoly A. Saveliev, Mikhail Soloviev, Theunis Piersma, Rob Dekker, Job ten Horn, C.J. Camphuysen, Eldar Rakhimberdiev, Anne Dekinga, Sjoerd Duijns, Joop Jukema, and Julia Karagicheva
- Subjects
0303 health sciences ,Multidisciplinary ,Operations research ,Computer science ,Science ,General Physics and Astronomy ,02 engineering and technology ,General Chemistry ,021001 nanoscience & nanotechnology ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Arctic ,13. Climate action ,Order (business) ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,lcsh:Q ,lcsh:Science ,0210 nano-technology ,030304 developmental biology - Abstract
Under climate warming, migratory birds should align reproduction dates with advancing plant and arthropod phenology. To arrive on the breeding grounds earlier, migrants may speed up spring migration by curtailing the time spent en route, possibly at the cost of decreased survival rates. Based on a decades-long series of observations along an entire flyway, we show that when refuelling time is limited, variation in food abundance in the spring staging area affects fitness. Bar-tailed godwits migrating from West Africa to the Siberian Arctic reduce refuelling time at their European staging site and thus maintain a close match between breeding and tundra phenology. Annual survival probability decreases with shorter refuelling times, but correlates positively with refuelling rate, which in turn is correlated with food abundance in the staging area. This chain of effects implies that conditions in the temperate zone determine the ability of godwits to cope with climate-related changes in the Arctic., Advancing phenological timing is a risk for migratory birds, particularly in the Arctic where change is most rapid. Here, the authors show that bar-tailed godwits can adjust for phenological shifts by fuelling faster at staging areas to arrive at breeding sites in time.
- Published
- 2018
39. Fuelling conditions at staging sites can mitigate Arctic warming effects in a migratory bird
- Author
-
Richard Reijnders, Walter Beentjes, Paul S. Ruiters, Luc Knijnsberg, Piet Veldt, C.J. Camphuysen, Julia Karagicheva, Jan A. van Gils, Anatoly A. Saveliev, Anatoly Gavrilov, Leo Heemskerk, Sjoerd Duijns, André E. van Loon, Theunis Piersma, Piet Admiraal, T. Lee Tibbitts, Mikhail Soloviev, Rob Dekker, G.O. Keijl, Arnold Wijker, Marc van Roomen, Eldar Rakhimberdiev, Anne Dekinga, Henk Levering, Job ten Horn, Joop Jukema, Vrs Castricum, and Piersma group
- Subjects
0106 biological sciences ,Science ,Climate Change ,General Physics and Astronomy ,Breeding ,010603 evolutionary biology ,01 natural sciences ,General Biochemistry, Genetics and Molecular Biology ,Charadriiformes ,Abundance (ecology) ,Flyway ,Temperate climate ,Animals ,lcsh:Science ,Staging area ,Probability ,Multidisciplinary ,Phenology ,Ecology ,Arctic Regions ,010604 marine biology & hydrobiology ,Global warming ,General Chemistry ,Survival Analysis ,Publisher Correction ,Tundra ,Arctic ,13. Climate action ,Environmental science ,lcsh:Q ,Animal Migration ,Seasons - Abstract
Under climate warming, migratory birds should align reproduction dates with advancing plant and arthropod phenology. To arrive on the breeding grounds earlier, migrants may speed up spring migration by curtailing the time spent en route, possibly at the cost of decreased survival rates. Based on a decades-long series of observations along an entire flyway, we show that when refuelling time is limited, variation in food abundance in the spring staging area affects fitness. Bar-tailed godwits migrating from West Africa to the Siberian Arctic reduce refuelling time at their European staging site and thus maintain a close match between breeding and tundra phenology. Annual survival probability decreases with shorter refuelling times, but correlates positively with refuelling rate, which in turn is correlated with food abundance in the staging area. This chain of effects implies that conditions in the temperate zone determine the ability of godwits to cope with climate-related changes in the Arctic.
- Published
- 2018
40. Conditions at the breeding grounds and migration strategy shape different moult patterns of two populations of Eurasian golden plover Pluvialis apricaria
- Author
-
Paula Machin, Magdalena Remisiewicz, Raymond H. G. Klaassen, Joop Jukema, Juan Fernandez-Elipe, Both group, and Piersma group
- Subjects
0106 biological sciences ,primary moult ,Pluvialis ,AVIAN PRIMARY MOLT ,Population ,Zoology ,010603 evolutionary biology ,01 natural sciences ,STARLINGS STURNUS-VULGARIS ,010605 ornithology ,GEOGRAPHICAL VARIATION ,WING-MOLT ,Seasonal breeder ,life cycle ,moult-breeding overlap ,education ,Ecology, Evolution, Behavior and Systematics ,education.field_of_study ,ANNUAL CYCLE ,biology ,BIRDS ,SANDPIPER CALIDRIS-MARITIMA ,Plover ,biology.organism_classification ,Annual cycle ,BODY-MASS ,Feather ,visual_art ,SWEDISH LAPLAND ,visual_art.visual_art_medium ,Animal Science and Zoology ,JUVENILE MOLT ,Moulting ,geographic locations - Abstract
Events in the life cycle of migrant birds are generally time-constrained. Moult, together with breeding and migration, is the most energetically demanding annual cycle stages, but it is the only stage that can be scheduled at different times of the year. However, it is still not fully understood what factors determine this scheduling.We compare the timing of primary feather moult in relation to breeding and migration between two populations of Eurasian golden plover Pluvialis apricaria, the continental population breeding in Scandinavia and in N Russia that migrates to the Netherlands and southern Europe, and the Icelandic population that migrates mainly to Ireland and western UK. Moult was studied at the breeding grounds (N Sweden, N Russia, Iceland) and at stopover and wintering sites (S Sweden, the Netherlands). In both populations, primary moult overlapped with incubation and chick rearing, and females started on average 9 d later than males. Icelandic plovers overlapped moult with incubation to a larger extent and stayed in the breeding grounds until primary moult was completed. In contrast, continental birds only moulted the first 5-7 primaries at the breeding grounds and completed moult in stopover and wintering areas, such as S Sweden and the Netherlands.This overlap, although rare in birds, can be understood from an annual cycle perspective. Icelandic plovers presumably need to initiate moult early in the season to be able to complete it at the breeding grounds. The latter is not possible for continental plovers as their breeding season is much shorter due to a harsher climate. Additionally, for this population, moulting all the primaries at the stopover/wintering site is also not possible as too little time would remain to prepare for cold-spell movements. We conclude that environmental conditions and migration strategy affect the annual scheduling of primary feather moult in the Eurasian golden plover.
- Published
- 2018
41. BODY FAT DISTRIBUTION AND GENETIC VARIANTS ARE ASSOCIATED WITH SEX DIFFERENCES IN SERUM LEPTIN AND ADIPONECTIN CONCENTRATIONS
- Author
-
H.J. Lamb, K. Willems van Dijk, Joop Jukema, J. van Klinken, R. de Mutsert, Christa M. Cobbaert, Tim Christen, Ingrid M. Jazet, M. den Heijer, F.R. Rosendaal, Raymond Noordam, S. Trompet, Internal medicine, AGEM - Endocrinology, metabolism and nutrition, Amsterdam Movement Sciences - Rehabilitation & Development, Amsterdam Movement Sciences - Restoration and Development, and APH - Aging & Later Life
- Subjects
medicine.medical_specialty ,Endocrinology ,Adiponectin ,Internal medicine ,Serum leptin ,medicine ,Genetic variants ,Biology ,Cardiology and Cardiovascular Medicine ,Body fat distribution - Published
- 2018
42. P2263Diagnostic performance of quantitative flow ratio in diabetic and non-diabetic patients
- Author
-
M El Mahdiui, Gerhard Koning, Joop Jukema, J.J. Bax, J.H.C. Reiber, A R Van Rosendael, Arthur J.H.A. Scholte, and Jeff M. Smit
- Subjects
Flow ratio ,medicine.medical_specialty ,business.industry ,Urology ,medicine ,Cardiology and Cardiovascular Medicine ,business ,Non diabetic - Published
- 2018
43. P4635Referral of patients for fractional flow reserve using quantitative flow ratio
- Author
-
Victoria Delgado, J.J. Bax, Arthur J.H.A. Scholte, Joop Jukema, Bart Mertens, Jeff M. Smit, M.J. Schalij, Gerhard Koning, A R Van Rosendael, M El Mahdiui, and J.H.C. Reiber
- Subjects
Flow ratio ,business.industry ,Medicine ,Mechanics ,Fractional flow reserve ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
44. Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6
- Author
-
Farid Radmanesh, Kenneth Rice, Xiuqing Guo, Jessica van Setten, Konstantin Strauch, Albert V. Smith, Jeffrey Haessler, Stefan Kääb, Folkert W. Asselbergs, Patricia B. Munroe, Steven A. Lubitz, Ching-Ti Liu, Niek Verweij, Aaron Isaacs, Martina Müller-Nurasyid, Allan Linneberg, Jan A. Kors, Ozren Polasek, Kari Stefansson, Caroline Hayward, Daniel F. Gudbjartsson, Jonathan Marten, Olli T. Raitakari, Mark Eijgelsheim, Timothy J. Mead, Nona Sotoodehnia, Elsayed Z. Soliman, Hao Mei, Gianfranco Sinagra, Stefan Weiss, Torben Hansen, Michiel L. Bots, Mika Kähönen, Yalda Jamshidi, Xiaoqin Liu, Stefania Cappellani, Unnur Thorsteinsdottir, Nilesh J. Samani, Cecilia W. Lo, Honghuang Lin, Charles Kooperberg, Moritz F. Sinner, Zhijun Xie, Jennifer A. Brody, Paolo Gasparini, Ruifang Li-Gao, Leo-Pekka Lyytikäinen, Stefan van Duijvenboden, Nikolai Klena, Michele Orini, Stella Trompet, Joop Jukema, Tamara B. Harris, Jerome I. Rotter, Stephan B. Felix, Julia Ramirez, Sheila Ulivi, Ioanna Ntalla, Marcus Dörr, Annette Peters, Paul L. Huang, Dennis O. Mook-Kanamori, Igor Rudan, Cornelia M. van Duijn, Christopher P. Nelson, Anna F. Dominiczak, Henry Völzke, Terho Lehtimäki, Niels Grarup, Henry J. Lin, Bruno H. Stricker, Tim D. Spector, Molly Schwartz, Patrick T. Ellinor, Vilmundur Gudnason, Uwe Völker, Christopher Newton-Cheh, Antonietta Robino, Marten E. van den Berg, Çağrı Güleç, Marco V Perez, Jette Bork-Jensen, Pim van der Harst, Rudolf A. de Boer, Jonathan Rosand, Oluf Pedersen, Susan R. Heckbert, David O Arnar, Dan E. Arking, André G. Uitterlinden, Andrew Tinker, Bram P. Prins, Lenore J. Launer, Alvaro Alonso, Leanne M. Hall, Helen R. Warren, Man Li, Pier D. Lambiase, Jørgen K. Kanters, Ilonca Vaartjes, James G. Wilson, Sandosh Padmanabhan, Melanie Waldenberger, Nathan A. Bihlmeyer, Peter van der Meer, Francesco J. Conti, George C. Gabriel, Hilma Holm, Gardar Sveinbjornsson, Suneel S. Apte, Annamaria Iorio, Blair H. Smith, Bruce M. Psaty, RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, RS: CARIM - R1.01 - Blood proteins & engineering, RS: FHML MaCSBio, Biochemie, Jamshidi, Yalda [0000-0003-0151-6482], Apollo - University of Cambridge Repository, Medical Informatics, Epidemiology, Internal Medicine, Læknadeild (HÍ), Faculty of Medicine (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), School of Engineering and Natural Sciences (UI), Verkfræði- og náttúruvísindasvið (HÍ), Háskóli Íslands (HÍ), University of Iceland (UI), Prins, Bram P, Mead, Timothy J, Brody, Jennifer A, Sveinbjornsson, Gardar, Ntalla, Ioanna, Bihlmeyer, Nathan A, van den Berg, Marten, Bork-Jensen, Jette, Cappellani, Stefania, Van Duijvenboden, Stefan, Klena, Nikolai T, Gabriel, George C, Liu, Xiaoqin, Gulec, Cagri, Grarup, Niel, Haessler, Jeffrey, Hall, Leanne M, Iorio, Annamaria, Isaacs, Aaron, Li-Gao, Ruifang, Lin, Honghuang, Liu, Ching-Ti, Lyytikäinen, Leo-Pekka, Marten, Jonathan, Mei, Hao, Müller-Nurasyid, Martina, Orini, Michele, Padmanabhan, Sandosh, Radmanesh, Farid, Ramirez, Julia, Robino, Antonietta, Schwartz, Molly, van Setten, Jessica, Smith, Albert V, Verweij, Niek, Warren, Helen R, Weiss, Stefan, Alonso, Alvaro, Arnar, David O, Bots, Michiel L, de Boer, Rudolf A, Dominiczak, Anna F, Eijgelsheim, Mark, Ellinor, Patrick T, Guo, Xiuqing, Felix, Stephan B, Harris, Tamara B, Hayward, Caroline, Heckbert, Susan R, Huang, Paul L, Jukema, J W, Kähönen, Mika, Kors, Jan A, Lambiase, Pier D, Launer, Lenore J, Li, Man, Linneberg, Allan, Nelson, Christopher P, Pedersen, Oluf, Perez, Marco, Peters, Annette, Polasek, Ozren, Psaty, Bruce M, Raitakari, Olli T, Rice, Kenneth M, Rotter, Jerome I, Sinner, Moritz F, Soliman, Elsayed Z, Spector, Tim D, Strauch, Konstantin, Thorsteinsdottir, Unnur, Tinker, Andrew, Trompet, Stella, Uitterlinden, André, Vaartjes, Ilonca, van der Meer, Peter, Völker, Uwe, Völzke, Henry, Waldenberger, Melanie, Wilson, James G, Xie, Zhijun, Asselbergs, Folkert W, Dörr, Marcu, van Duijn, Cornelia M, Gasparini, Paolo, Gudbjartsson, Daniel F, Gudnason, Vilmundur, Hansen, Torben, Kääb, Stefan, Kanters, Jørgen K, Kooperberg, Charle, Lehtimäki, Terho, Lin, Henry J, Lubitz, Steven A, Mook-Kanamori, Dennis O, Conti, Francesco J, Newton-Cheh, Christopher H, Rosand, Jonathan, Rudan, Igor, Samani, Nilesh J, Sinagra, Gianfranco, Smith, Blair H, Holm, Hilma, Stricker, Bruno H, Ulivi, Sheila, Sotoodehnia, Nona, Apte, Suneel S, van der Harst, Pim, Stefansson, Kari, Munroe, Patricia B, Arking, Dan E, Lo, Cecilia W, Jamshidi, Yalda, Medical Biochemistry, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, AII - Infectious diseases, AGEM - Endocrinology, metabolism and nutrition, AGEM - Inborn errors of metabolism, Amsterdam institute for Infection and Immunity, Amsterdam Gastroenterology Endocrinology Metabolism, Radiotherapy, Experimental Immunology, Gastroenterology and Hepatology, Graduate School, Intensive Care Medicine, Cardiology, Cardiovascular Centre (CVC), and Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)
- Subjects
0301 basic medicine ,ADAMTS6 ,Conduction ,Exome chip ,Meta-analysis ,Male ,Gene Expression ,Genome-wide association study ,Sudden cardiac death ,Electrocardiography ,Mice ,ADAMTS Proteins ,PR INTERVAL ,Exome ,lcsh:QH301-705.5 ,Exome sequencing ,POPULATION ,education.field_of_study ,Gen ,Ecology ,Adamts6 ,Exome Chip ,COMMON VARIANTS ,Middle Aged ,cardiovascular system ,Female ,Electrical conduction system of the heart ,QRS DURATION ,lcsh:QH426-470 ,Evolution ,Population ,Black People ,Computational biology ,Biology ,Polymorphism, Single Nucleotide ,White People ,WORSENING HEART-FAILURE ,03 medical and health sciences ,QRS complex ,Open Reading Frames ,Behavior and Systematics ,VENTRICULAR CONDUCTION ,Heart Conduction System ,Cardiac conduction ,Exome Sequencing ,medicine ,Genetics ,Erfðafræði ,Animals ,Humans ,ARRHYTHMIC DEATH ,cardiovascular diseases ,GENOME-WIDE ASSOCIATION ,education ,Ecology, Evolution, Behavior and Systematics ,Research ,Gene Expression Profiling ,Myocardium ,MORTALITY ,Rannsóknir ,Cell Biology ,medicine.disease ,lcsh:Genetics ,030104 developmental biology ,lcsh:Biology (General) ,Genetic Loci ,Connexin 43 ,ELECTROCARDIOGRAPHIC PARAMETERS ,Genome-Wide Association Study - Abstract
Publisher's version (útgefin grein)., Background: Genome-wide association studies conducted on QRS duration, an electrocardiographic measurement associated with heart failure and sudden cardiac death, have led to novel biological insights into cardiac function. However, the variants identified fall predominantly in non-coding regions and their underlying mechanisms remain unclear. Results: Here, we identify putative functional coding variation associated with changes in the QRS interval duration by combining Illumina HumanExome BeadChip genotype data from 77,898 participants of European ancestry and 7695 of African descent in our discovery cohort, followed by replication in 111,874 individuals of European ancestry from the UK Biobank and deCODE cohorts. We identify ten novel loci, seven within coding regions, including ADAMTS6, significantly associated with QRS duration in gene-based analyses. ADAMTS6 encodes a secreted metalloprotease of currently unknown function. In vitro validation analysis shows that the QRS-associated variants lead to impaired ADAMTS6 secretion and loss-of function analysis in mice demonstrates a previously unappreciated role for ADAMTS6 in connexin 43 gap junction expression, which is essential for myocardial conduction. Conclusions: Our approach identifies novel coding and non-coding variants underlying ventricular depolarization and provides a possible mechanism for the ADAMTS6-associated conduction changes., Funding This work was funded by a grant to YJ from the British Heart Foundation (PG/12/38/29615). AGES: This study has been funded by NIH contracts N01-AG-1-2100 and 271201200022C, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00–063. The researchers are indebted to the participants for their willingness to participate in the study. ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. Funding support for “Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium” was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). BRIGHT: The Exome Chip genotyping was funded by Wellcome Trust Strategic Awards (083948 and 085475). This work was also supported by the Medical Research Council of Great Britain (Grant no. G9521010D); and by the British Heart Foundation (Grant no. PG/02/128). AFD was supported by the British Heart Foundation (Grant nos. RG/07/005/23633 and SP/08/005/25115); and by the European Union Ingenious HyperCare Consortium: Integrated Genomics, Clinical Research, and Care in Hypertension (grant no. LSHM-C7–2006-037093). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. We would also like to thank the Barts Genome Centre staff for their assistance with this project. CHS: This Cardiovascular Health Study (CHS) research was supported by NHLBI contracts HHSN268201800001C, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants R01HL068986, U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ERF: The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013)/grant agreement HEALTH-F4–2007-201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254). The ERF study was further supported by ENGAGE consortium and CMSB. High-throughput analysis of the ERF data was supported by joint grant from Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). We are grateful to all study participants and their relatives, general practitioners, and neurologists for their contributions to the ERF study and to P Veraart for her help in genealogy, J Vergeer for the supervision of the laboratory work, and P Snijders for his help in data collection. FHS: The Framingham Heart Study (FHS) research reported in this article was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI), HL120393. Generation Scotland: Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping of the Generation Scotland and Scottish Family Health Study samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, Edinburgh, Scotland and was funded by the UK’s Medical Research Council. GOCHA: The Genetics of Cerebral Hemorrhage with Anticoagulation was carried out as a collaborative study supported by grants R01NS073344, R01NS059727, and 5K23NS059774 from the NIH–National Institute of Neurological Disorders and Stroke (NIH-NINDS). GRAPHIC: The GRAPHIC Study was funded by the British Heart Foundation (BHF/RG/2000004). NJS and CPN are supported by the British Heart Foundation and is a NIHR Senior Investigator. This work falls under the portfolio of research supported by the NIHR Leicester Cardiovascular Biomedical Research. INGI-FVG: This study has been funded by Regione FVG (L.26.2008). INTER99: The Inter99 was initiated by Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee comprises the former two and Charlotta Pisinger. The study was financially supported by research grants from the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk Inc., Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). JHS: We thank the Jackson Heart Study (JHS) participants and staff for their contributions to this work. The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Dr. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences. KORA: The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. Korcula: This work was funded by the Medical Research Council UK, The Croatian Ministry of Science, Education and Sports (grant 216–1080315-0302), the Croatian Science Foundation (grant 8875), the Centre of Excellence in Personalized health care, and the Centre of Competencies for Integrative Treatment, Prevention and Rehabilitation using TMS. LifeLines: The LifeLines Cohort Study and generation and management of GWAS genotype data for the LifeLines Cohort Study are supported by The Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation, and Dutch Diabetes Research Foundation. Niek Verweij is supported by NWO-VENI (016.186.125) and Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, Project ID: 661395). UHP: Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Ilonca Vaartjes is supported by a Dutch Heart Foundation grant DHF project “Facts and Figures.” MGH-CAMP: Dr. Patrick Ellinor is funded by NIH grants (2R01HL092577, 1R01HL128914, R01HL104156, and K24HL105780) and American Heart Association Established Investigator Award 13EIA14220013 (Ellinor). Dr. Steve Lubitz is funded by NIH grants K23HL114724 and a Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105. NEO: The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants, and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk, and Ingeborg de Jonge for the coordination, lab, and data management of the NEO study. We also thank Arie Maan for the analyses of the electrocardiograms. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). RS-I: The generation and management of the Illumina Exome Chip v1.0 array data for the Rotterdam Study (RS-I) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The Exome chip array dataset was funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, from the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO)-sponsored Netherlands Consortium for Healthy Aging (NCHA; project nr. 050–060-810); the Netherlands Organization for Scientific Research (NWO; project number 184021007); and by the Rainbow Project (RP10; Netherlands Exome Chip Project) of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbmri.nl). We thank Ms. Mila Jhamai, Ms. Sarah Higgins, and Mr. Marijn Verkerk for their help in creating the exome chip database, and Carolina Medina-Gomez, MSc, Lennard Karsten, MSc, and Linda Broer PhD for QC and variant calling. Variants were called using the best practice protocol developed by Grove et al. as part of the CHARGE consortium exome chip central calling effort. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. The work of Bruno H. Stricker is supported by grants from the Netherlands Organization for Health Research and Development (ZonMw) (Priority Medicines Elderly 113102005 to ME and DoelmatigheidsOnderzoek 80–82500–98-10208 to BHS). The work of Mark Eijgelsheim is supported by grants from the Netherlands Organization for Health Research and Development (ZonMw) (Priority Medicines Elderly 113102005 to ME and DoelmatigheidsOnderzoek 80–82500–98-10208 to BHS). SHIP: SHIP is supported by the BMBF (grants 01ZZ9603, 01ZZ0103, and 01ZZ0403) and the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG]; grant GR 1912/5–1). SHIP and SHIP-TREND are part of the Community Medicine Research net (CMR) of the Ernst-Moritz-Arndt University Greifswald (EMAU) which is funded by the BMBF as well as the Ministry for Education, Science and Culture and the Ministry of Labor, Equal Opportunities, and Social Affairs of the Federal State of Mecklenburg-West Pomerania. The CMR encompasses several research projects that share data from SHIP. The EMAU is a member of the Center of Knowledge Interchange (CKI) program of the Siemens AG. SNP typing of SHIP and SHIP-TREND using the Illumina Infinium HumanExome BeadChip (version v1.0) was supported by the BMBF (grant 03Z1CN22). We thank all SHIP and SHIP-TREND participants and staff members as well as the genotyping staff involved in the generation of the SNP data. TWINSUK: TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. UKBB: This research has been conducted using the UK Biobank Resource (application 8256 - Understanding genetic influences in the response of the cardiac electrical system to exercise) and is supported by Medical Research Council grant MR/N025083/1. We also wish to acknowledge the support of the NIHR Cardiovascular Biomedical Research Unit at Barts and Queen Mary University of London, UK. PD Lambiase acknowledges support from the UCLH Biomedicine NIHR. MO is supported by an IEF 2013 Marie Curie fellowship. JR acknowledges support from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007–2013) under REA grant agreement no. 608765. YFS: The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation of Finnish Diabetes Association. The expert technical assistance in the statistical analyses by Irina Lisinen is gratefully acknowledged. Cell culture and biochemistry: Funding was provided by the National Institutes of Health (Program of Excellence in Glycoscience award HL107147 to SSA and F32AR063548 to TJM) and the David and Lindsay Morgenthaler Postdoctoral Fellowship (to TJM) and by the Allen Distinguished Investigator Program, through support made by The Paul G. Allen Frontiers Group and the American Heart Association (to SSA). Mutant mouse model: Adamts6 mutant mice were generated and further propagated and analyzed by funding provided by NIH grants HL098180 and HL132024 (to CWL) and by the Allen Distinguished Investigator Program, through support made by The Paul G. Allen Frontiers Group and the American Heart Association (to SSA).
- Published
- 2018
45. Study protocol: a randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over
- Author
-
Claudia-Martina Messow, Robin P. Peeters, David J. Stott, B. C. van Munster, R. S. du Puy, Bruce H. R. Wolffenbuttel, Iris Postmus, Joop Jukema, Olaf M. Dekkers, Simon P. Mooijaart, W.P.J. den Elzen, Manuel R. Blum, Ian Ford, Patricia M. Kearney, Sharon Kean, Rosalinde K. E. Poortvliet, Johannes W. A. Smit, Torquil Watt, Jacobijn Gussekloo, Rudi G. J. Westendorp, Nicolas Rodondi, Value, Affordability and Sustainability (VALUE), Lifestyle Medicine (LM), Center for Liver, Digestive and Metabolic Diseases (CLDM), Molecular Neuroscience and Ageing Research (MOLAR), and Internal Medicine
- Subjects
Male ,Pediatrics ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Placebo-controlled study ,Levothyroxine ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,DISEASE ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Subclinical hypothyroidism ,Clinical endpoint ,030212 general & internal medicine ,Functional ability ,610 Medicine & health ,VERSION ,Subclinical infection ,Netherlands ,80-plus ,Randomised controlled trial ,Aged, 80 and over ,Age Factors ,General Medicine ,Treatment Outcome ,Female ,360 Social problems & social services ,medicine.drug ,Quality of life ,medicine.medical_specialty ,endocrine system ,QUESTIONNAIRE ,030209 endocrinology & metabolism ,Placebo ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Double-Blind Method ,Hypothyroidism ,medicine ,Humans ,VALIDITY ,THYPRO ,lcsh:RC648-665 ,business.industry ,ADULTS ,R1 ,Clinical trial ,Thyroxine ,business ,Follow-Up Studies - Abstract
BACKGROUND: Subclinical hypothyroidism is common in older people and its contribution to health and disease needs to be elucidated further. Observational and clinical trial data on the clinical effects of subclinical hypothyroidism in persons aged 80 years and over is inconclusive, with some studies suggesting harm and some suggesting benefits, translating into equipoise whether levothyroxine therapy provides clinical benefits. This manuscript describes the study protocol for the Institute for Evidence-Based Medicine in Old Age (IEMO) 80-plus thyroid trial to generate the necessary evidence base.METHODS: The IEMO 80-plus thyroid trial was explicitly designed as an ancillary experiment to the Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism randomised placebo controlled Trial (TRUST) with a near identical protocol and shared research infrastructure. Outcomes will be presented separately for the IEMO and TRUST 80-plus groups, as well as a pre-planned combined analysis of the 145 participants included in the IEMO trial and the 146 participants from the TRUST thyroid trial aged 80 years and over. The IEMO 80-plus thyroid trial is a multi-centre randomised double-blind placebo-controlled parallel group trial of levothyroxine treatment in community-dwelling participants aged 80 years and over with persistent subclinical hypothyroidism (TSH ≥4.6 and ≤ 19.9 mU/L and fT4 within laboratory reference ranges). Participants are randomised to levothyroxine 25 or 50 micrograms daily or matching placebo with dose titrations according to TSH levels, for a minimum follow-up of one and a maximum of three years. Primary study endpoints: hypothyroid physical symptoms and tiredness on the thyroid-related quality of life patient-reported outcome (ThyPRO) at one year. Secondary endpoints: generic quality of life, executive cognitive function, handgrip strength, functional ability, blood pressure, weight, body mass index, and mortality. Adverse events will be recorded with specific interest on cardiovascular endpoints such as atrial fibrillation and heart failure.DISCUSSION: The combined analysis of participants in the IEMO 80-plus thyroid trial with the participants aged over 80 in the TRUST trial will provide the largest experimental evidence base on multimodal effects of levothyroxine treatment in 80-plus persons to date.TRIAL REGISTRATION: Nederlands (Dutch) Trial Register: NTR3851 (12-02-2013), EudraCT: 2012-004160-22 (17-02-2013), ABR-41259.058.13 (12-02-2013).
- Published
- 2018
46. A critical appraisal of pharmacogenetic inference
- Author
-
Roelof A.J. Smit, Raymond Noordam, Joop Jukema, Stella Trompet, and S. le Cessie
- Subjects
0301 basic medicine ,Pharmacogenomic Variants ,Computer science ,Inference ,Bioinformatics ,statins ,03 medical and health sciences ,Drug treatment ,Genetics ,Humans ,Precision Medicine ,Set (psychology) ,Genetics (clinical) ,pharmacogenetics ,Clinical Trials as Topic ,inference ,Interpretation (philosophy) ,Clinical study design ,Research ,Data science ,Critical appraisal ,030104 developmental biology ,Phenotype ,Research Design ,epidemiology ,Disease Susceptibility ,Hydroxymethylglutaryl-CoA Reductase Inhibitors - Abstract
In essence, pharmacogenetic research is aimed at discovering variants of importance to gene-treatment interaction. However, epidemiological studies are rarely set up with this goal in mind. It is therefore of great importance that researchers clearly communicate which assumptions they have had to make, and which inherent limitations apply to the interpretation of their results. This review discusses considerations of, and the underlying assumptions for, utilizing different response phenotypes and study designs popular in pharmacogenetic research to infer gene-treatment interaction effects, with a special focus on those dealing with of clinical effects of drug treatment.
- Published
- 2018
47. Discovering patterns of pleiotropy in genome-wide association studies
- Author
-
Harold Snieder, Moritz F. Sinner, Daniel F. Gudbjartsson, Niek Verweij, PM Pramstaller, B. D. Mitchell, Stephan B. Felix, Elsayed Z. Soliman, R. J. F. Loos, T.B. Harris, Mika Kähönen, Philipp S. Wild, Christy L. Avery, Kirill V. Tarasov, Stefania Bandinelli, Stefan Kääb, Tim D. Spector, Patrick T. Ellinor, David J. Stott, Renate B. Schnabel, Igor Rudan, O Polasekd, Brendan M. Buckley, Thomas Meitinger, James F. Wilson, Honghuang Lin, Gandin Ilaria, CM Duijn van, James P. Brody, L. J. Launer, Xiaoyan Yin, Ritchie, CT Aldana Silva, Paolo Gasparini, Dan M. Roden, Diane M. Crawford, Eric Boerwinkle, Davíð O. Arnar, Annette Peters, Caroline Hayward, Ilja M. Nolte, Terho Lehtimäki, Joop Jukema, Pi Bakker de, Thomas Münzel, Steven R. Cummings, Henry Völzke, Peter W. Macfarlane, John Barnard, Fabiola M Del Greco, Dan E. Arking, Anna F. Dominiczak, Patricia B. Munroe, Jonathan D. Smith, Anne M. Butler, Bruno H. Stricker, Stefan Blankenberg, Pv Harst der, S. Ulivi, Jerome I. Rotter, Hilma Holm, Alvaro Alonso, Haonan Lin, Gianfranco Sinagra, Alexander Teumer, Q Gibson, Bruce M. Psaty, Uwe Völker, Olli T. Raitakari, Annamaria Iorio, Bouwe P. Krijthe, Lude Franke, Folkert W. Asselbergs, Jared W. Magnani, G. Ehret, Susan R. Heckbert, L Ferrucci, Edward G. Lakatta, N. Sotoodehnia, Harry Campbell, Toshiko Tanaka, Wagoner van, JS Baderab, Yalda Jamshidi, Daniel S. Evans, David Schlessinger, Kari Stefansson, Nilesh J. Samani, Martina Müller-Nurasyid, Mark Eijgelsheim, Vilmundar Gudnason, Brenton R. Swenson, Sina A. Gharib, Kathleen F. Kerr, Josh C. Denny, Maristella Steri, E J Benjamin, George J. Papanicolaou, Unnur Thorsteinsdottir, Ivana Kolcic, Yuki Bradford, Mina K. Chung, Yongmei Liu, M. Waldenberger, Stella Trompet, Hoed, Jv Setten, Tanja Zeller, Jan A. Kors, Francesco Cucca, Irene Mateo Leach, A.G. Uitterlinden, Albert V. Smith, Craig Muller, Andrew A. Hicks, A Isaacs, Leo-Pekka Lyytikäinen, Konstantin Strauch, Steven A. Lubitz, Antonietta Robino, J Zhana, A. Pfeufer, Sandosh Padmanabhan, Afshin Parsa, Harm-Jan Westra, Marcus Dörr, and J. C. Bis
- Subjects
False discovery rate ,Linkage disequilibrium ,Genotype-phenotype distinction ,Pleiotropy ,Genotype ,SNP ,Genome-wide association study ,Computational biology ,Biology ,Genetic association - Abstract
MotivationGenome-wide association studies have had great success in identifying human genetic variants associated with disease, disease risk factors, and other biomedical phenotypes. Many variants are associated with multiple traits, even after correction for trait-trait correlation. Discovering subsets of variants associated with a shared subset of phenotypes could help reveal disease mechanisms, suggest new therapeutic options, and increase the power to detect additional variants with similar pattern of associations. Here we introduce two methods based on a Bayesian framework, SNP And Pleiotropic PHenotype Organization (SAPPHO), one modeling independent phenotypes (SAPPHO-I) and the other incorporating a full phenotype covariance structure (SAPPHO-C). These two methods learn patterns of pleiotropy from genotype and phenotype data, using identified associations to discover additional associations with shared patterns.ResultsThe SAPPHO methods, along with other recent approaches for pleiotropic association tests, were assessed using data from the Atherosclerotic Risk in Communities (ARIC) study of 8,000 individuals, whose gold-standard associations were provided by meta-analysis of 40,000 to 100,000 individuals from the CHARGE consortium. Using power to detect gold-standard associations at genome-wide significance (0.05 family-wise error rate) as a metric, SAPPHO performed best. The SAPPHO methods were also uniquely able to select the most significant variants in a parsimonious model, excluding other less likely variants within a linkage disequilibrium block. For meta-analysis, the SAPPHO methods implement summary modes that use sufficient statistics rather than full phenotype and genotype data. Meta-analysis applied to CHARGE detected 16 additional associations to the gold-standard loci, as well as 124 novel loci, at 0.05 false discovery rate. Reasons for the superior performance were explored by performing simulations over a range of scenarios describing different genetic architectures. With SAPPHO we were able to learn genetic structures that were hidden using the traditional univariate tests.Availabilityhttps://bitbucket.org/baderlab/fast/wiki/Home. SAPPHO software is available under the GNU General Public License, v2.
- Published
- 2018
48. Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group
- Author
-
David J. Stott, Jin Li, James G. Wilson, Nona Sotoodehnia, Y-Di Chen, Elsayed Z. Soliman, L. A. Cupples, Yongmei Liu, Henry J. Lin, Stephanie M. Gogarten, James S. Floyd, J. C. Bis, Susan R. Heckbert, Linda Broer, Dennis O. Mook-Kanamori, Jeffrey Roach, T.B. Harris, Kerri L. Wiggins, Melanie D. Napier, Joop Jukema, Vilmundur Gudnason, Robert C. Kaplan, Xiaohui Li, Cathy C. Laurie, P.E. Slagboom, Raul Mendez-Giraldez, Kenneth Rice, Kirk C. Wilhelmsen, Jennifer A. Brody, Jan A. Kors, Naveed Sattar, Evan L. Busch, Daniel S. Evans, Stella Trompet, Albert V. Smith, Amanda A. Seyerle, L. J. Launer, Til Stürmer, Raymond Noordam, Ruifang Li-Gao, Bruce M. Psaty, Yun Li, Jerome I. Rotter, Frits R. Rosendaal, Bruno H. Stricker, Kathleen F. Kerr, Kent D. Taylor, John D. Eicher, Steve Cummings, James D. Stewart, Christy L. Avery, R. de Mutsert, Colleen M. Sitlani, Andrew D. Johnson, Leslie A. Lange, Qing Duan, A.G. Uitterlinden, Eric A. Whitsel, Alexander P. Reiner, Epidemiology, Internal Medicine, and Medical Informatics
- Subjects
0301 basic medicine ,Male ,Genome-wide association study ,Type 2 diabetes ,Pharmacology ,Cardiovascular ,Electrocardiography ,Ethnicity ,Medicine ,Pharmacology & Pharmacy ,Pharmacology and Pharmaceutical Sciences ,Middle Aged ,3. Good health ,Heart Disease ,Cardiovascular Diseases ,Cardiology ,Molecular Medicine ,Female ,Patient Safety ,Type 2 ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Pharmacogenomic Testing ,Article ,03 medical and health sciences ,QRS complex ,Clinical Research ,Internal medicine ,Diabetes Mellitus ,Genetics ,Humans ,Adverse effect ,Aged ,Cytochrome P-450 CYP2C9 ,business.industry ,Human Genome ,Repeated measures design ,Genetic Variation ,medicine.disease ,030104 developmental biology ,Sulfonylurea Compounds ,Good Health and Well Being ,Diabetes Mellitus, Type 2 ,Pharmacogenetics ,Pharmacogenomics ,business ,Genome-Wide Association Study - Abstract
Sulfonylureas, a commonly-used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In eleven ethnically diverse cohorts that included 71 857 European, African American, and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT, and QRS intervals. In ancestry-specific meta-analyses, 8 novel pharmacogenomic loci met the threshold for genome-wide significance (P < 5 x 10−8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated with sulfonylurea-related treatment effects and other adverse drug reactions in previous studies was replicated. Additional research is needed to replicate the novel findings and to understand their biological basis.
- Published
- 2018
49. Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice
- Author
-
Joop Jukema, Stella Trompet, and Chris J. Packard
- Subjects
medicine.medical_specialty ,Apolipoprotein B ,Endocrinology, Diabetes and Metabolism ,Disease ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Genetics ,medicine ,Humans ,Routine clinical practice ,030212 general & internal medicine ,Risk factor ,Molecular Biology ,Apolipoproteins B ,Nutrition and Dietetics ,biology ,business.industry ,Cell Biology ,Cardiovascular Diseases ,Practice Guidelines as Topic ,biology.protein ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Published
- 2018
50. Geographic variation in morphometrics, molt, and migration suggests ongoing subspeciation in Pacific Golden-Plovers (Pluvialis fulva)
- Author
-
Joop Jukema, Johan G. van Rhijn, Theunis Piersma, and Piersma group
- Subjects
Morphometrics ,subspeciation ,biology ,Pluvialis ,Ecology ,Range (biology) ,wing length ,Geographic variation ,geographic variation, migration, molt, Pacific Golden-Plover, Pluvialis fulva, subspeciation, wing length, wing pointedness ,geographic variation ,migration ,biology.organism_classification ,Pluvialis fulva ,Tundra ,wing pointedness ,Pacific Golden-Plover ,Flyway ,molt ,Animal Science and Zoology ,Ecology, Evolution, Behavior and Systematics - Abstract
Breeding Pacific Golden-Plovers (Pluvialis fulva) cover 140 longitudinal degrees of Arctic tundra. Having examined 557 museum skins from across this huge distributional range, we conclude that Pacific Golden-Plovers breeding in Alaska are structurally larger than those breeding in Siberia, especially in wing length. Birds from Alaska also have more pointed wings and almost always postpone the initiation of primary molt until they reach their winter quarters, whereas many Siberian birds start primary molt in the breeding areas. These differences could have been favored by the longer transoceanic flights followed by the Alaskan populations to nonbreeding destinations in the Pacific Islands. We propose that the Alaskan and Siberian breeding birds be distinguished as distinct flyway populations to be used in conservation assessments by the international conservation community.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.